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ABSTRACT
The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in 
malignant transformation, prevention of apoptosis, drug resistance and metastasis. 
The expression of this pathway is frequently altered in breast cancer due to mutations 
at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, 
TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast 
cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are 
associated with a better prognosis than breast cancers lacking these mutations. The 
expression of this pathway and upstream HER2 has been associated with breast cancer 
initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes 
drug metformin can suppress the growth of breast CICs and herceptin-resistant 
HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/
mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant 
examples from other cancer types. The targeting of this pathway will be discussed 
as well as clinical trials with novel small molecule inhibitors. The targeting of the 
hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in association 
with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway. 
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INTRODUCTION 
Breast cancer is a leading cause of cancer-related 
death in women. This disease is diagnosed in nearly 1.4 
million women and is responsible for more than 450,000 
death every year [1]. According to the WHO release, 
there has been a 20% increase in the number of reported 
worldwide breast cancer patients which resulted in 
522,000 deaths since 2008. According to the US National 
Cancer Institute, approximately 232,000 occur resulting in 
about 40,000 deaths in the USA each year. Breast cancer is 
not gender specific [2,3]. The frequency of breast cancer 
in men is approximately 100-fold lower than in women as 
approximately 2,200 males will be diagnosed with breast 
cancer each year in the USA. 
Breast Cancer Genetics.
A prominent risk factor for the onset of breast 
cancer is age; however factors linked to lifestyle and diet 
also play important roles in breast cancer. Mutations at 
or deregulation of certain genes (BRCA1, BRCA2, HER2, 
PIK3CA) and others play important roles in breast cancer 
[4-18]. Mutations or aberrant or deregulated expression 
of TP53, MDM2 and RB also can play roles in the 
therapeutic responses of breast cancer [19-26]. Restoration 
of functional TP53 activity can increase the sensitivity of 
some TP53 mutant cells to certain anticancer drugs [27]. 
BRCA Genes and Other Genes Involved in DNA 
Repair Are Implicated in Breast Cancer.
Breast cancer occurrence is attributed to both 
genetic and environmental factors. Some breast cancers 
are due to hereditary mutations, namely those involving 
BRCA1 and BRCA2. BRCA1 encodes breast cancer type 
1 susceptibility protein which is involved in DNA repair 
and is considered a caretaker gene. The BRCA1 protein 
interacts with RNA polymerase II and also with histone 
deacetylase complexes [28]. BRCA1 plays key roles in 
transcription, repair of breaks in double stranded DNA as 
well as ubiquitination. The BRCA1 protein also combines 
with other proteins which detect DNA damage and other 
cell signals and forms a multi-subunit protein complex 
known as the BRCA1-associated genome surveillance 
complex (BASC) [29]. Components of this complex may 
be mutated in certain cancers. 
BRCA2 is also involved in the repair of DNA 
double strand breaks [30]. BRCA2 binds single stranded 
DNA. BRAC2 interacts with the RAD51 recombinase 
to stimulate strand invasion which is a critical step in 
homologous recombination. For RAD51 to bind the DNA 
double-strand breaks, a complex of BRCA1/partner and 
localizer of BRCA2 (PALB2)/BRCA2 is required [31].
The risk of developing breast or ovarian cancer 
in individuals with certain cancer-associated BRCA1/
BRCA2 alleles is 60-80% for breast cancer and 20-
40% for ovarian cancer. These individuals also develop 
cancer at an earlier age. In addition, other genes involved 
in DNA repair and signaling are implicated in breast 
cancer including: Fanconi anemia (FA) genes (FANCD2, 
FANCA and FANCC), mismatch repair genes (MutL 
homolog 1 [MLH1], MutS protein homolog 2 [MSH2], 
PMS1 protein homolog 1 [PMS1], mutS homolog 6 
[MSH6]), mismatch repair endonuclease PMS2 [PMS2] 
and DNA repair genes (Ataxia telangiectasia mutated 
[ATM], Ataxia telangiectasia and Rad3 related [ATR] 
and serine/threonine-protein kinases Chk/2 (CHK1/2), 
and the tumor suppressor genes (TP53, Serine/threonine 
kinase 11 [STK11] also known as liver kinase B1[LKB1], 
phosphatase and tensin homolog [PTEN]) and protein 
phosphatase 6 (PP6) [32-44]. 
In an important study with triple negative breast 
cancer (TNBC) patients, the frequency of BRCA1 and 
BRCA2 mutations and survival was examined [45]. 
DNA was isolated from tumor samples as well as normal 
tissues from 77 TNBC patients and the genetic sequence 
of the BRCA1/2 exons and flanking regions determined. 
19.5% of the TNBC patients had BRCA mutations, 
15.6% were mutant at BRCA1, and 3.9% were mutant 
at BRCA2. It turns out that the patients with BRCA 
mutations were younger than the patients with WT 
BRCA genes. In this study which followed the patients 
for up to 214 months, there were 42.9% recurrences and 
45.5% deaths. Interestingly, the five-year recurrence-
free survival estimates were associated with the genetic 
status of the BRCA genes. As the five-year recurrence-free 
survival rates were 51.7% for patients with WT BRCA 
genes whereas they were 86.2% for patients with BRCA 
mutations. 
BRCA1 and BRCA2 are also mutated in patients 
with ovarian cancer [46]. BRCA1/2 mutations are present 
in approximately 11 to 15% of unselected ovarian cancer 
patients. BRCA1 mutations were positively associated with 
TP53 mutations. The presence of BRCA1/2 mutations after 
platinum chemotherapy were associated with improved 
progression free survival. 
Hereditary and Sporadic Breast and Ovarian 
Cancer. 
Many spontaneous breast cancers are associated 
with environmental exposures to carcinogens [47-
61]. These include: air pollution [52], exposure to 
polychlorinated biphenyl congeners [53]. Pesticides 
[54,58], electromagnetic radiation [55], cadmium 
and nickel [56], radiation from medical imaging [59], 
acrylamide [61] and other toxins. 
Deregulation of BRCA1 expression has been 
implicated in sporadic breast cancer. The trinucleotide-
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repeat-containing 9 (TNRC9) gene has been shown to 
downregulate BRCA1 expression which results in breast 
cancer aggressiveness. TNRC9 is amplified in certain 
breast cancer patients and is associated with a poor 
prognosis [62]. This group also determined that ectopic 
expression of TNRC9 affected breast cancer cell survival. 
TNRC9 and BRCA1 protein expression were inversely 
correlated in large data sets of breast and ovarian cancer 
samples. Interesting this group determined that TNRC9 
bound to both the BRCA1 promoter and the cAMP-
responsive element-binding protein (CREB) complex. 
CREB is a regulator of BRCA1 transcription. Finally 
TNRC9 expression suppressed BRCA1 expression by 
altering the methylation status of the BRCA1 promoter 
region.
BRCA mutations have also been detected in familial 
and sporadic ovarian cancer patients. Germline mutations 
in BRCA1 or BRCA2 are present in approximately 18% 
of hereditary ovarian cancers. These mutations confer 
an estimated risk from 15 to 50% in the ovarian cancer 
patients [63].
In this study, the prevalence of BRCA1 mutations 
in 106 familial Greek ovarian cancer patients who had a 
strong family history of ovarian cancer or metachronous 
breast cancer. Metachronous breast cancer refers to a 
breast cancer patient which has two different breast 
cancers which occur at two different times, the two cancers 
can occur in the same breast. In addition, the prevalence of 
BRCA1 mutations were examined in 592 sporadic Greek 
ovarian cancer patients. In Greece, it had been previously 
determined that there were 6 types of BRCA1 mutations 
that accounted for 63% of all the mutations in the BRCA1 
and BRCA2 genes. Deleterious BRCA1 mutations were 
observed in 40.6% of familial ovarian cancer cases and 
4.6% of sporadic ovarian cases. This study determined 
that 71.2% of the BRCA1 carriers presented a high-grade 
serous phenotype. These studies document the importance 
of identifying BRCA mutations in breast and/or ovarian 
cancer families. The authors have stated that all serous 
ovarian cancer patients should consider genetic testing. 
Hereditary breast cancer often results from 
disruption of the normal functions of BRCA1 and BRCA2. 
In contrast BRCA1/BRCA2 are not necessarily mutated in 
sporadic breast cancer, but there may be mutations in TP53 
and epigenetic alterations which change the expression 
of other genes. These changes result in breast cancer 
cells which may be wild WT at BRCA1 and BRCA2 but 
have defects in DNA repair. In addition certain sporadic 
breast cancers may have hypermethylation of the BRCA1, 
estrogen receptor (ER), progesterone receptor (PR) and 
other genes which prevents or lowers their expression. 
These changes may results in the breast cancer cells 
having a mutant BRCA phenotype which is referred to as 
“BRCAness”. These breast cancers arise at early age and 
are aggressive [64]. 
In one study, the frequencies of methylation in the 
BRCA1 promoter region were examined in 96 sporadic 
invasive breast carcinomas and 43 sporadic ovarian 
carcinomas. Methylation of the BRCA promoter region 
was detected in 11% and 5% of the breast and ovarian 
carcinomas respectively. Methylation of the BRCA1 
promoter was linked with lack of ER and PR expression 
in these tumors [65]. 
Alterations of Genes Involved in DNA Repair in 
Breast Cancer. 
Sporadic breast cancers accounts for approximately 
70% of breast cancers, while familiar breast cancers 
account for the remaining 30% which are due to the 
present of mutations in breast cancer families (familiar 
breast cancers) [66]. Familial breast cancer families have 
a higher incidence of breast cancers. There exist different 
susceptibility genes which are high-, moderate-, and low-
penetrance susceptibility genes. High-penetrance genes 
include: BRCA1, BRCA2, PTEN and TP53, which in many 
cases are responsible at least in part for the familiar breast 
cancer. Other genes have been associated with moderate 
penetrance and risk. These include genes involved in DNA 
repair, such as CHEK2, ATM, BRIP1 (FANCJ), PALB2 
(FANCN) and RAD51C (FANCO). In addition, genes 
involved in low penetrance and risk are being identified. 
The presence of mutations at these different types of breast 
cancer susceptibility genes may be examined in breast 
cancer screening in the future.
The genetic structures of the TP53, BRCA1, ATM, 
and PIK3CA genes were examined in 145 Bulgarian 
patients with sporadic breast cancer. The expression of 
HER2 was examined by immunohistochemistry and 
chromogenic hybridization in situ (CISH) [67]. In this 
study, mutations were observed: at TP53 in 22.07% of 
the patients, at BRCA1 in 0.69% of the patients, at ATM 
in 7.59% of the patients, and in 31.25% of the patients 
at PIK3CA. Overexpression of HER2 was observed in 
21.21% of the patients. Mutations at TP53 were associated 
with both tumor size and grade of malignancy. Mutations 
at ATM were associated with grade of malignancy. 
Mutations at PIK3CA were associated with PR+ tumors. 
HER2 overexpression was correlated with the age of 
the patient when diagnosed with breast cancer, tumor 
size and ER+. This important study documented that 
TP53 mutations were an indicator for poorer outcome. 
Importantly, in this study the presence of two genetic 
mutations did not correlate with either a more aggressive 
carcinoma or a poorer overall survival. 
Chk2 is an important kinase which is activated in 
response to DNA damage. Chk2 is involved both in TP53 
and cell-cycle pathways. In some Li-Fraumeni syndrome 
families, which have germline mutations at TP53, 
mutations at CHK2 have also be observed. The presence 
of loss of heterozygosity (LOH) at the CHK2 gene was 
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examined in 139 breast cancer tumors [68]. 139 breast 
tumors were screened for loss of heterozygosity (LOH) at 
chromosome 22q (where the CHK2 gene is located), using 
seven microsatellite markers, LOH was detected in 53% of 
the breast tumors. Further studies examined the mutational 
status of the CHK2 gene and a germ line variant (T59K) in 
the first coding exon was detected. Upon screening 1172 
cancer patients with different types of cancer for the T59K 
sequence variant, it was detected in four breast cancer 
patients. This study concluded that CHK2 mutations were 
rare in breast cancer but the CHK2 gene product may 
perform a tumor suppressor function. 
Effects of c-Myc Overexpression in BRCA1-
Deficient Breast Cancer Patients. 
Elevated c-Myc expression leads to a poor prognosis 
in sporadic breast cancer patients that are BRCA1-deficient 
[69]. In this important study, the presence of BRCA1 gene 
expression was examined in 374 sporadic breast cancer 
patients. BRCA1 expression was lacking in 60.4% of the 
breast cancer patients. Patients that lost BRCA1 expression 
often had more advanced breast cancer and were tumor 
node metastasis stage III positive, lymph node positive and 
overexpressed c-Myc. The presence of hypermethylation 
of the BRCA1 promoter region was examined. BRCA1 
promoter hypermethylation was observed in 16.4% of 
the breast cancer patients examined and was associated 
with BRCA1-, ER- , c-Myc overexpression, and the 
triple-negative phenotype. Thus loss of functional BRCA1 
expression combined with increased expression of c-Myc 
was associated with a poor prognosis.
Alteration of TP53 in Breast Cancer.
Dysregulation of the TP53 gene also occurs in 
sporadic breast cancer [70]. The genetic structure of the 
TP53 gene was examined in 136 unselected sporadic 
breast cancer patients’ tumors. Approximately 40% of the 
tumor samples had TP53 mutations. Moreover, this group 
postulated that these mutations were due to exposure of the 
breast cancer patients to environmental mutagens based on 
the frequency of G-T transversions and the incidence of 
guanosine mutations on the non-transcribed DNA strand 
of the TP53 gene. 
Polymorphisms of the TP53 gene have been 
observed to have prognostic and predictive values in cancer 
therapy. The presence of two TP53 gene polymorphisms, 
Arg72Pro and PIN3 (+16 bp) was observed in ninety-four 
women with sporadic breast cancer who were followed 
for a mean of 67.9 months after therapy [71]. This study 
determined that the different genotypes of the Arg72Pro 
and PIN3 (+16 bp) polymorphisms had no significant 
impact on survival in the sporadic breast cancer patients. 
However, this study observed that the patients which 
were treated with chemotherapy regmins without an 
anthracycline, that had the A2A2 genotype of the PIN3 
(+16 bp) polymorphism, had a poorer overall survival than 
other genotypes. Although some controversity exists on 
use of anthracyclines in breast cancer patients, those with 
the A2A2 genotype of PIN3 (+16bp) polymorphism may 
benefit. These important studies document the importance 
of genetics in personalized medicine. 
Epigenetic Modification of the ER genes in Breast 
Cancer. 
Methylation of the promoter region of the ER and 
other genes has been associated with their decreased 
expression. The methylation status of the ER-alpha 
promoter region was examined in 138 sporadic breast 
cancers. The ER-alpha promoter region was observed to be 
methylated in 60.1% (83/138) tumors, including 57 of 69 
of the tumors which did not express ER-alpha. This study 
determined that the probability of ER-alpha promoter 
methylation was increased in those cases that were ER-
alpha- and PR- [72]. 
In a study of 100 sporadic primary breast cancers 
of which 51 were ER-alpha- and 49 ER-alpha+, ER 
methylation was observed in 98% of ER- and 65% of ER+ 
tumor samples. ER- promoter region methylation was also 
associated with lack of PR expression and double receptor 
negative expression status of the breast cancer specimens 
[73]. 
The methylation of the ER-beta promoter region 
was examined in 178 sporadic breast cancer patients. 
ER-beta promoter methylation was observed in 44.9% 
of breast tumor samples. In contrast ER-beta promoter 
hypermethylation was detected in only 14.3% of patients 
with benign breast hyperplasia. 58% of the ER-beta- 
tumors exhibited ER-beta promoter region methylation 
whereas 36.7% of the ER-beta+-positive cases exhibited 
methylation at the ER-beta promoter region. As the 
levels of ER-beta promoter methylation increased- the 
levels of ER-beta protein detected decreased in the tumor 
samples. A strong correlation between ER-alpha promoter 
methylation and ER-beta promoter methylation was 
observed [74]. 
Expression of EGFR Family Members in Breast 
Cancer Patients. 
The EGFR family consists of four members. For 
the sake clarity in this review, we will refer to them as 
EGFR1 (a.k.a., EGFR, HER1, c-erbB1), HER2 (a.k.a., 
EGFR2, c-erbB2), EGFR3 (a.k.a., c-erbB3, HER3) and 
EGFR4 (a.k.a., c-erbB4, HER4). The expression of the 
EGFR1, HER2, EGFR3 and EGFR4 were examined by 
immunohistochemistry in 220 breast cancer carcinomas 
[75]. Increased expression of EGFR1 was detected in 
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16.4% of the tumors, increased expression of HER2 was 
observed in 22.8% of the tumors, increased expression of 
EGFR3 was detected in 17.5% of the tumors, and increased 
expression of EGFR4 was observed in 11.9% of tumors. 
Breast cancer patients with tumors that overexpressed 
EGFR1, HER2 or EGFR3 had reduced survival. In 
contrast, those breast cancer patients whose tumors 
displayed elevated levels EGFR4 had better survival than 
the breast cancer patient that expressed EGFR1, HER2 
or EGFR3. Thus overexpression of EGFR1, HER2 and 
EGFR3 was association with a poor prognosis in breast 
cancer patients. In contrast, overexpression of EGFR4 
is associated with a good prognosis. In addition, this 
group investigated the association of ER expression with 
the different EGFR molecules. Expression of EGFR1, 
HER2 and EGFR3 was associated with ER negativity in 
the breast cancer patients. Moreover those breast cancer 
patients that were ER+ and also EGFR1+, HER2+ or 
EGFR3+ had poorer survival than those breast cancer 
patients which were either ER+ and HER2+ or EGFR4+.
Additional studies were performed by the same 
group on the proliferative potential of the different types 
of EGFR-expressing cells [76]. These important studies 
suggest that EGFR1, HER2 and EGFR3 are linked with 
tumor proliferation, while EGFR4 did not appear to drive 
proliferation but may even play protective roles.
In another study, the expression of the EGFR1 and 
EGFR3 proteins were examined in 104 primary breast 
carcinomas comprising nine comedo ductal carcinoma 
in situ (DCIS), 91 invasive ductal carcinomas and four 
invasive lobular carcinoma by histochemistry. Increased 
expression of EGFR3 was observed in 67% of comedo 
DCIS, 52% of invasive ductal carcinomas, 71% of 
carcinomas containing both the in situ and invasive lesions 
and 25% of invasive lobular carcinomas [77]. 59% of ER- 
tumors, 63% of lymph node+ tumors and 63% of HER2 
tumors were positive for EGFR3 expression. 67% of 
EGFR1+, 67% of HER2+ (67%), 75% TP53+ and 60% of 
cathepsin-D+ DCIS were positive for EGFR3 expression. 
The expression of EGFR1, HER2, EGFR3 and 
EGFR4 was examined in 100 breast cancer patients [78]. 
By using immunohistochemistry techniques, 36% of the 
breast cancer samples were positive for EGFR1, 27%, of 
the breast cancer samples were positive of HER2, 26% 
of the breast cancer samples were positive for EGFR3 
and 82% of the breast cancer samples were positive for 
EGFR4. The expression of these genes was also examined 
by RT-PCR and the similar results were observed. An 
association between decreased disease-free survival and 
expression of HER2 was observed. Co-expression of 
EGFR1 and HER2 was associated with a worse prognosis. 
In contrast, expression of EGFR4 was associated with a 
better outcome. EGFR4 expression appeared to antagonize 
the effects on HER2 on clinical outcome in the breast 
cancer patients which expressed both.  
The link between ER-alpha and EGFR4 expression 
was examined in 103 breast cancer samples by both 
immunohistochemistry and RT-PCR [79]. In 25% of the 
breast cancer samples ER-alpha were not expressed. In 
addition, approximately 25% of them did not express 
EGFR4. About one-half of the ER-alpha- tumors did 
not express EGFR4 at both mRNA and protein levels. 
The luminal breast cancer cell lines MCF-7 and T47D 
cells expressed both ER-alpha and EGFR4. While the 
basal breast cancer line MDA-MB-231 and the HER2-
overexpressing SK-BR-3 line expressed neither. These 
results have suggested roles for EGFR4 in ER-alpha 
mediated signal transduction in breast cancer. 
The expression patterns of EGFR1, HER2, EGFR3 
and EGFR4 were examined by real-time RT-PCR in 
365 unselected primary breast cancers [80]. EGFR1 and 
HER2 were negatively associated with ER+ and PR+ 
breast cancers. In contrast, EGFR3 and EGFR4 were 
positively associated with ER+ and PR+ breast cancers. In 
a subsequent study with the ER-alpha+ breast cancer cell 
line MCF-7, beta-estradiol down regulated the expression 
of all four EGFR family member receptors as determined 
by RT-PCR. In contrast, the ER antagonist 4-hydroxy 
tamoxifen (4HT) inhibited the downregulation induced by 
beta-estradiol [81]. 
Gatekeeper Mutations in HER2. 
The T798M mutation in HER2 is considered a 
gatekeeper mutation as it affects the ability of small 
molecule inhibitors such as lapatinib to bind the ATP-
binding pocket and the mutation confers resistance to 
the inhibitor [82]. In studies by a different research 
group which were aimed at determining the mechanism 
of resistance of breast cancer cells containing the HER2 
T798M mutation to lapatinib, it was shown that the cells 
overexpressed EGFR ligands [83]. In BT474 and MCF10A 
breast cancer cells transfected with the construct encoding 
HER2-T798M mutation, elevated HER2 kinase activity 
was detected and lapatinib did not block phosphorylation 
of HER2, EGFR3 or downstream Akt and ERK1/2. 
Increased levels of EGFR2 associated with PI3Kp85 were 
detected in the transfected cells and the BT474/HER2-
T798M cells were also resistant to Herceptin. However 
these cells were sensitive to the pan-phosphoinositol-3-
kinase (PI3K) inhibitors BKM120 and XL147 but not the 
mitogen-activated protein kinase kinase1/2 (MEK1/2) 
inhibitor CI-1040. The BT474/HER2-T798M transfected 
cells expressed elevated levels of the EGFR ligands EGF, 
TGF-alpha, amphiregulin (AR), and heparin binding EGF 
(HB-EGF). Thus targeting breast cancers with both HER2 
inhibitors and PI3K inhibitors may be an appropriate 
technique to treat those breast cancer patients with HER2-
T798M mutations [84]. Other growth factors also bind the 
EGFR family of receptors including: EGF, schwannoma-
derived growth factor (SDGF), vaccinia growth factor 
(VGF), Neu differentiation factor (NDF) or neuregulins, 
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and heregulin. A diagram of EGFR family members is 
presented in Figure 1.
Roles of Aberrant mRNA Splicing in Sensitivity 
to Herceptin. 
The splice variant delete16HER2, which results 
from exon 16 skipping, has been shown to increase the 
transformation frequency of cancer cells. This mis-
splicing results in resistance to Herceptin. In contrast, 
retention of intron 8 of the HER2 gene after mRNA 
splicing results in the creation of herstatin which inhibits 
tumor cell proliferation. Likewise retention of intron 15 
during splicing of HER2 results in the p100 protein which 
also suppresses tumor cell proliferation [85]. 
Mutations at the EGFR Gene Family in Breast 
Cancer. 
HER2 is amplified in 20-25% of breast cancers. 
However, the roles of mutations/amplifications of other 
EGFR family members are not so clear. Mutations and 
amplifications of EGFR1 have been detected in breast 
cancer [86, 87]. In a study consisting of 70 TNBC 
patient samples, mutations in the kinase domain were 
detected in 11% of the samples. This study amplified the 
region spanning exons 18 to 21 of the EGFR1 gene. The 
investigators detected deletions in exon 19, which encodes 
part of the kinase domain. However, the authors indicated 
that these mutations appeared to be independent of the 
expression levels of the EGFR1 protein that were detected 
by immunohistochemistry. A diagram illustrating some of 
the effects of mutations/amplifications in EGFR1/HER2 
and other genes in breast and other cancers on signal 
transduction pathways is presented in Figure 2.
In addition, amplification of the EGFR1 gene 
has been detected in certain breast cancers [88]. The 
EGFR1 gene was amplified in approximately 6% of the 
breast cancer patients they examined (n =175) and the 
samples displayed increased EGFR1 expression. They 
also examined patient samples which had amplified the 
EGFR1 gene for hot-spot mutations in the EGFR1 gene. 
No mutations were detected in exons 19 and 21.
The presence of EGFR1 or HER2 gene amplification 
or overexpression was investigated in a series of 
metaplastic breast carcinomas (MBC) [89]. MBC are 
basal like tumors that account for less than 1% of all 
invasive mammary carcinomas. Nineteen of the 25 (76%) 
MBC examined overexpressed EGFR1. EGFR1 gene 
amplifications were detected in 37% of the tumors which 
overexpressed EGFR1. In contrast, only one case exhibited 
HER2 overexpression but HER2 gene amplification was 
not detected in this study of MBC. The authors pointed out 
that some of the tumors that overexpressed EGFR1, but 
did not have EGFR1 gene amplification, the expression of 
EGFR1 could have resulted from activating mutations in 
EGFR1, which resulted in its expression. 
In a subsequent study by the same group, the 
presence of EGFR1 amplification and activating mutations 
was examined in 47 MBC [90]. 32% of the samples 
exhibited overexpression of EGFR1. Within the subset 
that had EGFR overexpression, 34% had EGFR1 gene 
amplification. This group examined these MBC samples 
for the presence of activating mutations in exons 18, 19, 
20, and 21 of the EGFR1 gene. No activating mutations of 
EGFR1 in exons 18, 19, 20 and 21 were detected in these 
MBC patient samples.
The epidermal growth factor receptor variant III 
(EGFRvIII) is a genetic truncation of the EGFR1 gene. It 
encodes a constitutively-active truncated EGFR1 protein 
which has been implication in many types of cancers, 
(e.g., brain, breast, prostate and others) [91-103]. 
Figure 1: Epidermal Growth Factor Receptor Family. 
Conserved domains of the four different EGFR family members 
are indicated by similar shading. L = ligand binding domain, 
CR = cysteine-rich domains. TM = transmembrane domain. 
CT = C-terminal domain which contains the phosphorylation 
sites. JM = juxta membrane domain. HER2 does not bind a 
ligand. The kinase domain in ERB3 is defective. Alternative 
names for each receptor are written underneath each receptor. 
Ligands which bind the receptors are indicated in purple circles 
above the receptors. Epidermal growth factor (EGF), vaccinia 
growth factor (VGF), amphiregulin (AR), heparin binding-EGF 
(HB-EGF), schwannoma-derived growth factor (SDGF), Neu 
differentiation factor (NDF), heregulin, neuregulin. Arrows 
between receptors indicate possible heterodimer formation 
between various EGFR family receptors.
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Introduction of a construct encoding EGFRvIII 
into MCF-7 breast cancer cells resulted in HER2 
phosphorylation, which the authors suggested occurred 
through heterodimerization and cross-talk [91]. The MCF-
7/EGFRvIII transfectants had approximately a 3-fold 
increase in colony formation. MCF-7/EGFRvIII were 
more tumorigenic that MCF-7 cells in athymic nude 
The EGFRvIII protein is detected in various 
human cancers, but not in normal tissues. The presence 
of EGFRvIII mRNA was examined in primary invasive 
breast cancer by utilizing laser capture microdissection 
(LCM)/RT-PCR. A high incidence (67.8%) of EGFRvIII 
transcripts was observed in pure breast cancer cells 
[92]. Furthermore, 57.1% of the infiltrating breast 
carcinomas expressed both EGFR1 WT and EGFRvIII 
mRNA in the same tumor. In contrast, no detectable 
EGFRvIII mRNA was seen in samples of normal 
breast tissue. These expression results were further 
confirmed by immunohistochemical analysis. Thus 
there was co-expression of EGFRvIII and EGFR WT 
in some human invasive breast cancer tissue but not in 
normal breast samples. It must be pointed out that other 
studies consisting of 55 breast cancer cell lines and 170 
primary breast cancer did not observe similar results and 
the authors concluded that expression of EGFRvIII is 
extremely rare in breast cancer [93]. However, in a study 
by a different research group, the expression of EGFRvIII 
mRNA in women with breast cancer was examined by 
an RT-nested PCR. EGFRvIII mRNA was detected in 
the peripheral blood of 30% of 33 low risk, early stage 
patients, in 56% of 18 patients selected for neoadjuvant 
chemotherapy, in 63.6% of 11 patients with disseminated 
disease but not in any of 40 control women [94]. 
Interesting in the low risk, early stage patients, EGFRvIII 
expression was associated with ER- or HER2+. In another 
study of 225 breast cancer patients, the expression of 
EGFR1, phosphorylated EGFR1, and EGFRvIII, was 
examined by immunohistochemistry and the patient 
outcomes were also followed [95]. 48% of the patients 
displayed EGFR1, 54% of the patients were positive for 
phospho-EGFR, and 4% of the patients were positive for 
EGFRvIII. EGFR1 expression correlated with negative 
hormone receptor status, worse relapse-free survival and 
overall survival than those patients with did not express 
detectable EGFR1 [95]. Interestingly there did not appear 
to be any association between expression of phospho-
EGFR or EGFRvIII expression with clinical outcome. 
This study indicated that prognostic value of EGFR1 
expression was most important in the HER2+ and the ER-/
PR- subgroups.
EGFRvIII expression may down regulate PR 
expression in certain luminal B tumors [96]. These tumors 
are ER+ but are characterized as having an aggressive 
behavior which is 4HT resistant. This subset of breast 
cancers displays increased EGFR1, HER2 and downstream 
PI3K/PTEN/Akt/mTORC1 pathway activation [96,97].
EGFRvIII interacts with HER2 [98] and chemokine 
(C-X-C motif) receptor 4 (CXCR4) [99,100] to activate 
signaling pathways important in migration, invasion and 
tumorigenesis. These interactions between EGFRvIII and 
HER2 and CXCR4 may be prolonged in comparison to 
interactions between EGFR1 and HER2 and CXCR4 as it 
is more difficult to down regulate the constitutive nature of 
EGFRvIII. CXCR4 is highly expressed in breast cancers 
and implicated in metastasis [101] and cancer initiating 
cells (CICs) [102].
Recently EGFRvIII has been implicated in primary 
breast cancers and breast CICs. Its expression has been 
associated with the Wnt/beta-catenin pathway and 
downstream beta-catenin target gene expression and 
the expression of genes associated with self-renewal. 
Its expression has been linked with increased in vitro 
mammosphere formation and tumor formation [103].
HER2 normally has to heterodimerize with another 
EGFR family member for activity. However, if the HER2 
gene is amplified, HER2 activity is induced and the 
abnormal breast tumor growth is dependent on HER2 
activity for growth [104]. An activating mutation has been 
detected in HER2+ lung cancer patients in the germline 
from a Japanese cancer patient with a familiar history of 
lung cancer as well as sporadic cancer patients [105]. The 
mutation occurred in the transmembrane region and may 
be responsible for increased stability and dimerization. 
This mutation activated downstream HER2 signaling 
molecules including Akt and p38MAPK. 
Somatic mutations in the kinase domain of the 
HER2 gene, which result in its activation have been 
detected in lung cancer patients [106]. In a study involving 
non small cell lung cancers (NSCLC), HER2 mutations 
were detected in 1.6% (11 of 671) of NSCLC cancer 
specimens examined but were absent in other types of 
cancers. The HER2 mutations were in-frame insertions 
in exon 20 corresponding to a similar region as in the 
EGFR gene where insertions were detected in NSCLC 
patients. Interestingly the HER2 mutations were more 
frequent in the lung cancer patients that never smoked. 
HER2 mutations were detected more frequently in patients 
of Oriental ethnicity than other ethnicities. The mutations 
were also more frequently detected in females. 
Recently mutations in HER2 have been detected 
in breast cancer patient samples which lack HER2 
gene amplification. Thirteen HER2 mutations were 
characterized from twenty-five patient samples which had 
HER2 mutations but lacked HER2 gene amplification. 
7 mutations were activating and resulted from point 
mutations and in-frame deletions. Some mutations 
(L755S) resulted in lapatinib resistance; however this was 
not an activating mutation. All of the cells containing the 
HER2 mutations were sensitive to the irreversible HER2 
kinase inhibitor, neratinib [107].
Loss of HER2 activity also results in loss of 
phosphorylated EGFR3. It has been shown that HER2 
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can dimerize with EGFR3 to drive breast cancer 
proliferation [104]. Loss of EGFR3 activity in HER2+ 
breast cancer cells inhibited their growth. This growth 
inhibition mediated by loss of HER2 or EGFR3 and could 
be overcome by introduction of a construct encoding 
activated Akt. Importantly this group demonstrated that 
a key function of EGFR3 was to couple the response of 
HER2 to the PI3K/PTEN/Akt/mTORC pathway.
Less is known about the roles of EGFR3 and EGFR4 
in breast cancer [108]. EGFR3 is naturally kinase-inactive. 
However it interacts with the EGFR family members 
and serves to transduce signals to the PI3K/PTEN/Akt/
mTORC1 pathway. Since EGFR3 is kinase-inactive, it 
will be more difficult to isolate inhibitors specific to it. 
However, it is still important and it can serve in pathways 
responsible for drug resistance [109]. 
The functions of EGFR4 in breast and other 
cancers have been investigated and recently summarized 
[110]. Similar to the EGFR1 gene, EGFR4 encodes a 
protein contains an extracellular ligand-binding domain, 
a hydrophobic transmembrane domain, an intracellular 
tyrosine kinase domain, and carboxyl-terminal tyrosine 
residues [110,111]. These carboxyl-terminal tyrosine 
residues are phosphorylated after ligand binding and 
allows coupling of the receptor with other signaling 
molecules [111]. Ligand binding to EGFR4 stimulates 
either homodimerization or heterodimerization of EGFR4 
with another EGFR family member. Activation of EGFR4 
signaling results in cleavage and release of the EGFR4 
cytoplasmic domain from the membrane, which then may 
traffic to the nucleus and mitochondria to exert additional 
biological effects [110,112,113].
The roles of EGFR4 in cancer are complex. In some 
cancers (larynx, pancreatic and prostate) EGFR4 may 
function as a tumor suppressor [110,114-116]. EGFR4 
expression in breast, cervical and ovarian cancers is 
associated with a favorable prognosis [110, 113,117,118]. 
The EGFR4 Q646C mutant results in an EGFR4 protein 
which undergoes ligand-independent homodimerization 
and tyrosine phosphorylation which interestingly 
suppresses colony formation of breast, pancreatic and 
prostate cell lines [110, 119-121]. Introduction of the 
constitutively active EGFR4 I658Q mutant into breast, 
ovarian and prostate cell lines induces apoptosis [122]. 
However, in some cell types and biological 
situations EGFR4 has oncogenic activities [120]. 
EGFR4 is overexpressed in certain cancers including 
ependymomas and medulloblastomas [111,116,123]. 
Overexpression of EGFR4 in lung carcinomas results 
in increased proliferation [116.123]. Furthermore, 
overexpression of HER2, EGFR4, and the EGFR4 ligand 
NRG1-beta in medulloblastoma results in increased 
metastasis [124]. Likewise over-expression of EGFR4 
in conjunction with EGFR1 and HER2 results in breast 
cancers correlates with poor prognosis [125]. In contrast 
overexpression of EGFR4 by itself results in a more 
favorable outcome. 
Silencing endogenous EGFR4 expression in 
ER+ MCF7 and T47D breast tumor cell lines reduces 
anchorage-independent proliferation stimulated by an 
EGFR4 ligand such as neuregulin-2beta [110, 126]. 
HER2 tyrosine kinase activity, rather than EGFR4 
tyrosine kinase activity was required for neuregulin-2beta 
to stimulate cell proliferation [110]. Interesting the sites 
of EGFR4 tyrosine phosphorylation, but not the sites of 
HER2 phosphorylation, were required for neuregulin-
2beta to regulate cell proliferation [110]. Thus the roles of 
EGFR4 in cancer remain complex and are influenced by 
the expression of other EGFR family members.
Neurofibromin 1 and GTPase Activating Proteins 
(GAP). 
Neurofibromin 1 (NF1) is a tumor suppressor 
gene. It encodes a GTPase which normally serves to 
regulate Ras signaling. It is mutated in neurofibromatosis 
patients. These patients have elevated (constitutive) Ras 
activation. The tumor suppressor NF1 has been implicated 
in sporadic breast cancer. Recent studies have suggested 
that NF1 is a breast cancer driver gene. NF1 is deleted 
or mutated in 27.7% of all breast carcinomas [127]. In 
a study of inbred Chaos3 mice, investigators noted high 
levels of genetic instability which can lead to mammary 
tumors. The genomically-characterized mammary 
adenocarcinomas from these mice displayed deletions of 
certain genes, and the NF1 gene was deleted in the vast 
majority of the mouse mammary adenocarcinomas. These 
mammary adenocarcinomas exhibited constitutive Ras 
hyperactivation and sensitivity to Ras pathway inhibitors.
Also alternative mRNA splicing events can give 
rise to different NF1 isoforms. NF1 and Ras expression 
were examined in 22 sporadic breast cancers, 18 benign 
lesions and 6 normal breast tissues by tissue microarrays. 
NF1 and CELF3-6 RNA expression was examined by 
RT-PCR in the breast samples. NF1 and Ras expression 
displayed no difference in expression when examined by 
immunohistochemistry assays. In contrast, NF1 isoforms 
were determined to shift from the type II mRNA isoform 
in normal breast in normal breast cancer to the type I 
mRNA isoform in breast carcinoma. The authors did not 
detect a shift in CELF mRNA cofactor expression that was 
related to the shift in NF1 mRNA isoforms. The authors 
suggest that there is a NF1 isoform shift in expression 
from type II to type I which could be important in the 
development and progression of sporadic breast cancer 
[128]. 
NF1 normally serves to regulate Ras and thus is 
implicated in the regulation of both the PI3K/PTEN/
Akt/mTORC1 and Raf/MEK/ERK pathways. Successful 
targeting of Ras may improve the therapy of patients 
with NF1 mutations. Alternatively, these patients may 
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be sensitive to combined treatment with MEK and PI3K 
pathway inhibitors.
Genes that serve to regulate the Ras gene may be 
tumor suppressors as when they are mutated the Ras 
pathway is turned on. The RasGAP2 gene (RASAL2) is one 
such gene, it is a tumor and metastasis suppressor which 
is mutated or suppressed in breast cancer. Inactivation of 
RASAL2 was shown to be associated with tumor growth, 
progression and metastasis in animal models. In human 
RASAL2 loss was associated with metastatic disease and 
decreased expression of RASAL2 was associated with the 
recurrence of luminal B breast tumors [129].
The methylation state of the Ras association domain-
containing protein 1 (RASSF1A) gene was examined in 36 
breast cancer patients in breast cancer tissue as well as their 
adjacent normal tissues [130]. RASSF1A may function as a 
tumor suppressor gene. Methylation of the RASSF1A gene 
was detected in 61.1% of the breast tissues but not in their 
normal adjacent tissues. The methylation of the RASSF1A 
gene resulted in deceases in mRNA and protein levels of 
33.3 and 44.4% respectively. In contrast, the RASSF1A 
protein was detected in normal tissues. Methylation of 
the RASSF1A gene did not appear to be associated with 
clinical parameters, such as age, histological types, TNM 
stages and lymph node metastases.
RAS Gene Family Mutations/Alterations in 
Breast Cancer.
In a genetic study examining the mutational status 
of the Ras and PI3K pathway genes in 40 breast cancer 
cell lines, mutations were detected at approximately 
25% in Ras pathway members (KRAS, HRAS, NRAS, 
and BRAF) and 54% of PI3K pathway members (PTEN, 
PIK3CA). However, unlike the mutational status of these 
two families in colo-rectal cancer, this study did not 
detect mutation in both pathway family genes in single 
cell lines very frequently [131]. In subsequent studies by 
the same group with 41 breast cancer cell lines, this group 
found 146 mutations among twenty-seven cancer causing 
genes, which resulted in an average of 3.6 mutations per 
cell line. Mutations in TP53, RB and PI3K pathways 
were frequently detected in the breast cancer cell lines. 
Importantly these investigators could identify mutational 
profiles that were associated with luminal-type and basal-
type breast cancer cell lines. The luminal mutational 
profile included E-cadherin (CDH1) and mitogen-activated 
protein kinase kinase 4 (MAP2K4 a.k.a. MEK4) genes 
and amplifications of the cyclin D1, (CCND1), HER2 and 
mouse double minute 2 homolog (MDM2), while the basal 
mutational profile included: BRCA1, RB1, RAS and BRAF 
gene mutations and deletions of tumor suppressors p16 
(CDKN2A) and p14ARF (CDKN2A a.k.a. INK4A) [132].
Activation of the Ras pathway is often detected in 
breast cancer in the absence of mutations of the RAS genes 
[133]. Gene expression signature analysis has revealed 
that Ras pathway dependence can predict the sensitivity to 
inhibitors targeting the Raf/MEK/ERK and PI3K/PTEN/
Akt/mTORC1 pathways. The Ras pathway activation 
is associated with sensitivity to MEK inhibitors but 
resistance to Akt inhibitors in breast and lung tumors. The 
Ras pathway signature is a better indicator of Ras pathway 
dependency than mutations at KRAS, as there can be 
many genetic mutations which can result in Ras pathway 
dependency (e.g., upstream receptors, EGFR1 and others 
as well as mutations in BRAF and other downstream 
signaling molecules). The Ras pathway signature was 
determined to be activated in breast cancers which were 
sensitive to MEK inhibitors but resistant to Akt inhibitors. 
The Ras pathway signature was shown to be increased 
in ER- breast cancers and lung adenocarcinomas. The 
Ras pathway signature also predicts resistant to the 
EGFR1-targeting agent cetuximab (Erbitux) in metastatic 
colorectal cancer [134]. 
Upon novel global gene expression profiling on 
47,293 gene transcripts in 128 invasive breast cancers, 
the Ras-like, estrogen-regulated, growth-inhibitor 
(RERG) gene was determined to be a key marker of the 
luminal BC class and could be used to separate distinct 
prognostic subgroups [135]. These observations were 
further explored by performing immunohistochemistry 
on tissue microarrays containing 1,140 invasive breast 
cancers [135]. These results showed that the RERG 
gene is one of the highest ranked genes to differentiate 
between ER+ luminal and ER- non-luminal cancers. 
RERG expression was positively associated with the 
following markers of luminal differentiation: ER+, the 
cytokeratins (CK7/8, CK18 and CK19) and FOXOA1. 
RERG expression was also associated with other markers 
of good prognosis namely, small size, lower histologic 
grade an d AR, BRCA1, fragile histidine triad protein 
(FHIT, Bis(5’-adenosyl)-triphosphatase), and p21Waf-1 and 
p27Kip-1 and inversely associated with the proliferation 
markers MIB1 (a monoclonal antibody which is directed 
to a different epitope on the Ki67 protein than the original 
Ki67 antibody) and TP53. Importantly RERG expression 
was associated with longer survival.  
The Rab-coupling protein RCP (a.k.a RAB11FIP1), 
is located at a chromosomal region frequently amplified 
in breast cancer. Introduction of constructs encoding RCP 
into normal human mammary epithelial cells MCF-10A 
cells lead to cells with tumorigenic properties. Likewise 
knock-down of RCP in breast cancer cell lines decreased 
the tumorigenic properties of the cells. Therefore RCP is a 
frequently amplified gene in breast cancer  and suggest 
roles for the Rab family in carcinogenesis [136].
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Interactions between Ras and Bmi-1 in Breast 
Cancer. 
The B-lymphoma Moloney murine leukemia virus 
insertion region-1 (Bmi-1) gene functions in stem cell 
maintenance. It is a member of the polycomb group 
of transcription repressors. Bmi-1 exerts it effects by 
suppression of the p16Ink4A/ARF tumor suppressor. 
Increased expression of Bmi-1 is detected in many cancers. 
The effects on Bmi-1 overexpression were examined on 
MCF-10A cells. While Bmi-1 overexpression by itself did 
not result in the oncogenic transformation of MCF-10A 
cell, co-expression of activated H-Ras (RasG12) resulted 
in the oncogenic transformation of MCF-10A cells. The 
Bmi-1/H-Ras transformed cells exhibited properties of 
cells that had undergone the epithelial to mesenchymal 
transition (EMT). Bmi-1 inhibited senescence and 
allowed the proliferation of cells expressing high levels 
of activated H-Ras [137]. Subsequent studies by the same 
group have indicated that knock-down of Bmi-1 in breast 
cancer cell lines decreased their aggressive nature in vivo 
in tumor transplant studies [138].
Mutations in Components of the PI3K/PTEN/Akt 
mTOR Pathway in Breast Cancer.
In a study which examined MBC, PIK3CA 
mutations were detected in 47.4% of the cancers which 
were aggressive and also chemoresistant. In contrast, 
PI3KCA mutations were detected in 34.5% of hormone 
receptor-positive cancers, 22.7% of 75 HER2-positive 
cancers, 8.3% of basal-like cancers and none of claudin-
low tumors examined in this study. MBCs and claudin-low 
breast cancer subsets displayed enrichment for markers 
linked to stem cell function and EMT. It was postulated 
that MBCs and claudin-low tumors are enriched with 
CICs and may arise from an earlier, more chemoresistant 
breast epithelial precursor than either basal-like or luminal 
cancers. However in this study, no mutations at PIK3CA 
were detected in the claudin-low cancers, so the roles of 
PIK3CA mutations in these cancers are not clear [139]. 
In a study with 547 human breast cancer patient 
samples and 41 established cell lines, the mutational 
status of PIK3CA, AKT and PTEN were analyzed as well 
as the effects of pathway mutations on the sensitivity to 
PI3K inhibitor LY294002 [140]. PIK3CA mutations were 
determined to be more frequent in ER+ (34.5%) and 
HER2+ (22.7%) than in basal-like tumors (8.3%). AKT1 
(1.4%) and PTEN (2.3%) mutations were determined to 
be restricted to ER+ breast cancers. Interestingly cells 
with PIK3CA mutations were less sensitive to the PI3K 
inhibitor LY294002 inhibitor than breast cancer cells 
which had loss of PTEN activity. Thus, PI3K pathway 
aberrations likely play a distinct role in the pathogenesis 
of different breast cancer subtypes. The specific aberration 
present may have implications for the selection of PI3K-
targeted therapies in hormone receptor-positive breast 
cancer.
In a study which examined the genetic structure of 
the PIK3CA gene in 452 breast cancer patients, PIK3CA 
mutations were observed in 33.4% of the breast cancer 
patients [141]. PIK3CA mutations were more frequently 
detected in ERalpha+ and PR+ breast cancers (41.1%), 
than in TNBCs (ER-,PR-, HER2-) (12.5%.). Patients 
which had PIK3CA mutations had a longer metastasis-free 
survival period than the overall population. 
The mutational status of the PIK3CA gene was 
examined in eighty HER2+ breast cancer patients as 
well as clinical outcome of the patients after Herceptin 
treatment [142]. The PIK3CA gene was determined to be 
mutated in 21.3% of HER2+ breast cancer patients that 
had been treated with herceptin for one year. Improved 
disease free survival was observed in those patients with 
WT PIK3CA as opposed to those patients with mutant 
PIK3CA. The PIK3CA gene is also mutated in some 
ovarian cancer patients [143]. 
PI3K-p110 (PIK3CA) protein expression was 
examined in 1,394 early stage breast cancer samples. 
Elevated PI3K-p110 was associated with the basal-like 
breast cancers, HER2+ breast cancer, and triple negative 
non-basal breast cancers. In contrast, the luminal class 
of breast cancers had reduced levels of PI3K-p110 in 
comparison to the other classes. PI3K-p110+ breast 
cancer patients had shorter disease free survival. Thus 
these studies demonstrated that PI3K-p110 expression is a 
biomarker associated with poor prognosis in breast cancer 
[144]. 
Interactions between PIK3CA Mutations and 
HER2 Amplification in Breast Cancer. 
Introduction of genetic constructs containing 
PIK3CA mutations E545K and H1047R into MCF-10A 
human mammary epithelial cells that also overexpress 
HER2 conferred enhanced growth properties to MCF10A/
HER2 cells in comparison to cells which lacked the 
introduced mutant PIK3CA gene [145]. Upon introduction 
of mutant PIK3CA (H1047) into MCF-10A cells which 
overexpress HER2, the expression of EGFR3/EGFR4 
ligand heregulin (HRG) was detected. In contrast, 
introduction of mutant PIK3CA (E545K) gene into the 
MCF-10A cells which overexpressed HER2 did not result 
in the expression of HRG. Silencing HRG with siRNA 
inhibited the growth of MCF-10A/HER2/PIK3CA-
H1047R cells but not MCF-10A/HER2/PIK3CA-E545K-
expressing cells. The HRG siRNA synergized with the 
HER2 inhibitors herceptin (trastuzumab) and lapatinib. 
Treatment of the cells with a PI3K inhibitor (BEZ235) 
suppressed HRG and P-AKT levels. When the cells 
were cotreated with BEZ235 and lapatinib, a complete 
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suppression of growth was observed. These important 
result document interactions between HER2 and certain 
PIK3CA mutations and point to the possible co-targeting 
of HER2 and PI3K in certain breast cancers. 
Deregulation of the PI3K/PTEN/Akt/mTORC1 
pathway by gene mutations has been estimated to occur 
in >70% of breast cancers [146]. In ER+ breast cancers, 
activation of the PI3K/PTEN/Akt/mTORC1 pathway 
can result in both estrogen-dependent and estrogen-
independent ER activity and contribute to estrogen-
independence and potentially loss of sensitivity to 
hormonal based therapies. Activation of the PI3K/PTEN/
Akt/mTORC1 pathway can also result in resistance to 
HER2 inhibitors in HER2+ cells. Inhibition of the PI3K/
PTEN/Akt/mTORC1 pathway can overcome resistant 
to hormonal and anti-HER2 targeted therapies [146]. 
Encouraging results have been obtained in breast cancer 
clinical trials with combinations of various inhibitors. 
These results predict that combinations of HER2, PI3K, 
mTORC2 inhibitors and hormonal based therapeutics may 
be appropriate for the treatment of certain breast cancer 
patients which are resistant to current therapies. 
The transforming activity of mutant PI3K has 
been linked to its ability to bind phosphorylated YXXM 
motifs present in activated receptor tyrosine kinases 
(RTK) or adaptor molecules, potentially in association 
with the PI3K-regulatory subunit, p85. EGFR3 is a 
potent activator of the PI3K/PTEN/Akt/mTORC1 
pathway. The requirement for EGFR3 in PI3K-mediated 
transformation of mammary epithelium was investigated 
[147]. Conditional loss of EGFR3 in mammary epithelium 
lead to a delay in PI3K-H1047R-mediated mammary 
hyperplasia. However, these studies demonstrated that 
tumor latency and PI3K signaling were not perturbed. In 
the EGFR3-deficient mammary tumors, the PI3K-H1407R 
protein was determined to be associated with several 
tyrosyl phosphoproteins. These studies also demonstrated 
that inhibition of other EGFR family members with 
lapatinib did not inhibit the mutant PI3K-mediated 
signaling. However, co-inhibition of PI3K with the PI3K-
alpha specific inhibitor BYL719 and EGFR-mediated 
signaling with lapatinib was more effective in suppressing 
growth than treatment with either the PI3K-alpha 
inhibitor or lapatinib alone. Additional studies by this 
group determined that co-inhibition of PI3K and EGFR 
suppressed growth and PI3K signaling in human breast 
cancer cells containing the mutant PIK3CA-H1047R gene. 
These studies point to the possibility of co-targeting of 
PI3K and EGFR in certain breast cancers. 
Mutations at PIK3CA and PTEN Can Confer 
Resistance to Herceptin in HER2+ Breast Cancer. 
An RNA interference screen was performed 
to identify some of the genes involved in resistance 
to herceptin. PTEN was identified as a modulator of 
resistance to Herceptin in cell cultures experiments. 
Likewise oncogenic PIK3CA mutations would confer 
resistance to Herceptin in cell cultures [148]. In a 
screening of samples from 55 breast cancer patients, 
PIK3CA mutations or low expression of PTEN was 
associated with resistance to Herceptin. 
Deregulation of PI3K and PTEN in Metastatic 
Breast Cancer. 
The mutational status of the PIK3CA gene and 
expression of PTEN was examined in breast cancer 
specimens that differed in the state of malignancy (e.g., 
primary vs. metastatic breast cancer from the same cancer 
patient) [149]. The PIK3CA gene was determined to be 
mutated in 19 (40%) of primary tumors and 21 (42%) of 
metastatic cancers. PTEN expression was examined by 
immunohistochemistry and PTEN expression was lost 
in 14 (30%) primary tumors and 13 (25%) metastases. 
Thus the PI3KCA gene is frequently mutated and PTEN 
expression is often lost in breast cancer.
Epigenetic Regulation of Additional and Novel 
Genes Associated with Breast Cancer. 
Epigenetic profiling has recently resulted in the 
identification of genes associated with breast cancer 
tumorigenicity that were methylated [150]. This study 
identified 264 hypermethylated loci in genomic CpG 
islands. Hierarchical clustering in terms of the levels of 
methylation at the loci resulted in generation of at least 
three distinct groups of breast cancer patients. Namely 
the methylation levels were distributed into three 
different groups, ER+/PR+ breast cancer patients, time 
to tumor relapse and lymph note metastasis. Methylation 
of six genes (RECK, SFRP2, UAP1L1, ACADL, ITR, 
and UGT3A1) was associated with decreased relapse 
free survival. Reversion-inducing-cysteine-rich protein 
with kazal motifs (RECK) is thought to be a metastasis-
suppressor gene and may interact negatively with matrix 
metalloproteinase (MMP9). Secreted frizzled-related 
protein 2 (SFRP2) is a soluble modulator of Wnt signaling. 
Methylation of this gene has been association with breast 
and other cancers [151]. UAP1L1 encodes a UDP-N- 
acteylglucosamine pyrophosphorylase 1-like 1 protein. 
ACADL is a member of the acyl-CoA dehydrogenase 
family. This is a family of mitochondrial flavoenzymes 
involved in fatty acid and branched chain amino-acid 
metabolism. The ACADL gene product is associated with 
long-chain 3-hydroxyacyl-coenzyme A dehydrogenase 
deficiency. The ITR gene (ITR/GPR180) is a G protein-
coupled receptor). The UGT3A1 gene is a member of the 
UDP glycosyltransferase 3 family.
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Drug Resistance and CICs. 
Drug resistance breast cancer cells are enriched 
in populations of cells which have characteristics of 
cancer stem cells. These cancer cells with stem like 
characteristics are referred to cancer initiating cells (CICs) 
[152-175]. In the study by Britton and colleagues with 
both clinical fine needle aspirates obtained from breast 
cancer patients as well as established breast cancer cell 
lines, the expression of ATP-binding cassette sub-family 
G member 2 (ABCG2=BCRP1) was monitored [175]. 
In the studies with the side populations from MCF-7 and 
MDA-MB-231 cells, increased ABCG2 was observed in 
the side populations as well as elevated resistance to the 
chemotherapeutic drug mitoxantrone. The increase in the 
side populations may be due to increased drug transporter 
expression in the cells with the CIC phenotype as the 
drug transporter would exclude the drugs from the cells. 
The presence of the side populations in the fine needle 
aspirates was associated with ER-negative breast cancers 
and TNBCs which also had elevated ABCG2 protein 
expression. Breast CICs can be characterized by increased 
expression of CD44 and decreased expression of CD24 
(CD44↑/CD24↓) compared to the remaining cancer cells 
which are referred to as the bulk cancer cells (BCs). The 
CICs and BCs differ in their gene expression patterns 
which may have resulted from epigenetic and other 
mechanisms [176]. Thus the CICs and BCs will likely 
have different signaling pathways activated/suppressed 
which will require different therapeutic approaches to 
eliminate both populations of cancer cells. 
Involvement of HER2 in Breast CICs.
HER2 is expressed in the CIC population [177, 
178]. The expression of HER2 is modulated by the tumor 
microenvironment. Targeting of HER2 in these CICs may 
be an appropriate therapeutic approach. Interestingly 
herceptin suppressed tumor growth of the CIC in mouse 
xenograft models but in not established breast tumors 
[176]. 
Initially was thought that herceptin would only be 
effective in breast cancer patients which overexpressed 
HER2, some clinical studies have shown that herceptin 
may target breast cells which did not overexpress HER2 
[179]. These results have led to the hypothesis that HER2 
is an important molecule expressed on breast CICs and 
further studies have suggested that HER2 expression 
may be induced by signals in the microenvironment in 
breast CICs which lack HER2 gene amplification.The 
effectiveness of herceptin is thought to be due to its ability 
to target the breast CIC population as well as the PI3K/
PTEN/Akt/mTORC and other signaling pathways [176, 
177, 180]. 
Herceptin may also be effective in the treatment of 
breast cancer patients which lack amplification of HER2, 
documenting a role for HER2 in the growth of these 
normally HER2-negative cancers [181]. These authors 
demonstrated that HER2 was expressed in ER+, HER2- 
luminal breast cancers and regulates the self renewal of 
the CIC sub-population. HER2 expression was not due 
to gene amplification but was determined to result from 
receptor activation of NF-kappaB (RANK)-ligand in the 
bone microenvironment.
PI3K Pathway in Breast CICs. 
The PIK3CA gene may be mutated in some breast 
CICs [182]. The PI3K/PTEN/Akt/mTORC pathway 
has been reported to be important in breast CICs. Side-
population positive MCF-7 breast cancer cells [MCF-7/
(CIC)] were isolated from parent MCF-7 bulk cancer 
[MCF-7/(BC)] [183]. The MCF-7/(CIC) cells displayed 
increased drug transporter activity and enhanced colony-
formation ability in vitro and greater tumorigenicity in 
vivo than the MCF-7/(BC). The expression of critical 
pathways were compared between MCF-7/(CIC) and 
MCF-7/(BC). The PI3K/PTEN/Akt/mTORC1 and STAT3 
pathways were shown to be differentially expressed in the 
MCF-7/(CIC) population and responsible in part for their 
enhanced survival [183]. 
Deregulation of Akt in Breast Cancer. 
Mutations of Akt are relatively rare in breast 
cancer, however, aberrant activation of either upstream 
PIK3CA or polymorphism of the PH domain and leucine 
rich repeat protein phosphatase 2 (PHLPP2) gene can 
result in Akt expression. In a study which examined 
the mutational status and polymorphism of genes in the 
PI3K/PTEN/Akt/mTORC1 pathway, DNA was isolated 
from fine needle aspirations of 267 stage I-III breast 
cancers [184]. In this study, 28 genes were examined for 
163 known cancer-related DNA sequence variations by 
Sequenom technology. The PI3K pathway was determined 
to be frequently altered in breast cancers as at least one 
mutation in 38 alleles corresponding to 15 genes in 
108 (40%) of the breast cancer samples. The PIK3CA 
gene was determined to be the most frequently mutated 
(16.1% of all samples), the F-box and WD repeat domain 
containing 7, E3 ubiquitin protein ligase (FBXW7) gene, 
the second (8%), the BRAF gene, the third (3.0%), the 
EGFR1 gene, the fourth (2.6%), the AKT1 and CTNNB1 
genes (beta-catenin) the fifth and sixth (1.9% each), the 
KIT and KRAS genes (1.5% each), and the PDGFRA 
gene, the seventh (1.1%). Polymorphism at the PHLPP2 
phosphatase which activates Akt was observed in 13.5% 
of the patient samples. PIK3CA mutations were observed 
more frequently in ER+ cancers compared to TNBC 
(19 vs. 8%). Interesting a high frequency of PIK3CA 
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mutations (28%) was observed in HER2+ breast tumors. 
In TNBC, FBXW7 mutations were significantly more 
frequent compared to ER+ tumors (13 vs. 5%). FBXWZ 
is a component of ubiquitin ligase (SKP-cullin-F-box) 
and may bind cyclin E and target it for ubiquitin-mediated 
degradation (Figure 2).
Some investigators have suggested that other 
molecules besides Akt are important in breast cancer and 
have proposed Akt-independent signaling mechanisms 
[185]. This group demonstrated that in some breast tumors 
cultured in an anchorage-independent fashion displayed 
minimal Akt activation and decreased reliance on Akt for 
growth. In contrast, these cells had strong PDK1 activation 
and membrane localization and were dependent on the 
activated PDK1 substrate serum/glucocorticoid regulated 
kinase family, member 3 (SGK3), which is related in 
structure to Akt. SGK3 has been shown in additional 
studies to be linked with breast cancer and is induced 
by estrogen in breast cancer cells and is associated with 
ER expression [186]. Like Akt, SGK3 can phosphorylate 
GSK-3beta and TSC-2 which results in their inactivation 
and activation of mTORC1 and stimulation of protein 
translation [187, 188]. Knowledge of the particular kinase 
or other type of protein, responsible for the malignant 
potential of breast cancer cells could aid therapy by the 
use of more effective inhibitors which target the particular 
enzyme affected and responsible for the abnormal growth.
Activated Akt as a Marker for Sensitivity to Drug 
Therapy. 
Phosphorylation (activation) of Akt has been shown 
to predict the effectiveness of paclitaxel chemotherapy in 
node-positive breast cancer patients [189]. In the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-28 trial, the effectiveness of adding paclitaxel to 
doxorubicin (a.k.a Adriamycin) plus cyclophosphamide 
(AC) was examined in breast cancer patients (median 
follow up 9.1 years). Enhanced effectiveness of adding 
paclitaxel to AC was observed in those breast cancer 
patients who expressed elevated P-Akt. In contrast, 
no enhanced effectiveness of adding paclitaxel to AC 
was detected in the breast cancer patients who did not 
express activated P-Akt. Thus addition of paclitaxel to 
breast cancer patients which are P-Akt- does not appear 
to increase the effect of AC therapy, while addition of 
paclitaxel to those breast cancer patients which are P-Akt+ 
does appear to improve therapy.
PTEN and Cytokines and their Involvement in 
HER2-Resistance and CIC Survival. 
PTEN is important in breast CIC survival. 
Knockdown of PTEN expression was shown to result in 
increases in normal and malignant human mammary stem/
progenitor cells both in vitro and in vivo. This increase in 
progenitor cells was mediated by increased Akt activation 
which resulted in the phosphorylation of GSK-3beta which 
in turn led to activation of the Wnt/beta-catenin pathway. 
The increases in progenitor cells could be suppressed by 
the Akt inhibitor perifosine [190]. PTEN is also important 
in the resistance of breast cancers to herceptin and other 
therapeutic approaches [191]. 
 Interleukin-6 (IL-6) is cytokine which is an 
important immune-regulator. IL-6 is also important in 
HER2-resistance as it can expand the CIC population 
[192-194]. Decreases in PTEN expression has been 
implicated in herceptin-resistance. In HER2+ cell lines 
generated by knocking down PTEN, which were resistant 
to herceptin, the resistance was shown to be due to 
activation of an IL-6 inflammatory feed back loop. This 
IL-6 inflammatory loop resulted in the expansion of breast 
CIC which have an EMT phenotype and secrete 100-fold 
more IL-6 than in the parental cells which did not have 
PTEN knocked down. The authors of this important study 
also determined than treatment with an IL-6R Ab inhibited 
this IL-6 regulatory loop and reduced the CIC population 
and importantly reduced tumor growth and metastasis 
in mouse xenographs. A figure depicting the effects of 
PTEN on certain CICs as well as ER-signaling is present 
in Figure 3.  
The tumor microenvironment is important in CICs. 
Interactions between the interleukin-8 receptor (IL-8R) 
and HER2 have been determined to be important in 
the survival of breast CICs [195]. NF-kappaB has been 
shown to be important in breast cancer CIC survival and 
HER2-dependent tumorigenesis. NF-kappaB activity can 
be regulated by the PI3K/PTEN/Akt/mTORC1 pathway 
[193]. 
Targeting PI3K Pathway to Inhibit Breast Cancer 
Resistance to Therapy. 
Treatment of breast cancer patients with the 
aromatase inhibitor (AI) letrozole has been shown to result 
in suppression of the PI3K/PTEN/Akt/mTORC1 pathway 
[194]. This clinical study examined the expression of PI3K 
(p110), P-Akt, and P-mTOR by immunohistochemistry on 
breast cancer samples from 113 patients. The patients had 
been enrolled in a phase II study of letrozole or letrozole 
and cyclphosphamide. Either letrozole or letrozole 
plus cyclophosphamide-treated patients displayed a 
reduction in PI3K and P-mTOR expression. In contrast, 
expression of P-Akt did not change in the letrozole-
treated patients whereas it decreased in the letrozole and 
cyclophosphamide-treated patients. The reduction of 
P-Akt expression was associated with a better response 
rate and reduction in Ki67 staining. The reduction in 
P-mTOR expression was associated with a longer disease-
free survival. Thus the AI letrozole targets key components 
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of the PI3K/PTEN/Akt/mTORC1 pathway which may be 
important in the successful treatment of certain breast 
cancers. 
This same group developed some letrozole-
resistant MCF-7 cells by culturing the cells for prolonged 
periods of time in letrozole. The letrozole-resistant cells 
displayed elevated expression of key components of the 
PI3K/PTEN/Akt/mTORC1 pathway. They observed that 
suppression of the PI3K/PTEN/Akt/mTORC1 pathways 
with PI3K or mTORC1 inhibitors reversed the acquired 
letrozole- resistance [195]. A diagram of the effects of 
letrozole on ER and PI3K/PTEN/Akt/mTORC signaling 
and letrozole-resistance is presented in Figure 4. 
Effects of PI3K/PTEN/Akt/mTORC1 Pathway 
Activation and ER Expression on Breast Cancer. 
PIK3CA mutations in ER+/HER2- luminal 
breast cancer actually result in low levels of mTORC1 
expression and these breast cancers have some of the 
better treatment successes after 4HT therapy [196]. These 
PIK3CA mutations are predicted to render these breast 
cancers sensitive to targeted therapy. The authors of this 
study have devised a PIK3CA gene expression pattern. 
This pattern was associated with prognosis in those breast 
cancers with PIK3CA mutations that remained ER+/
HER2-, it was not associated with prognosis in breast 
cancers which were either HER2+ or ER-.
An inverse relationship between PI3K pathway 
activation and ER expression was observed in ER+ 
breast cancers. When the PI3K pathway was activated, 
lower levels of ER were detected, indicating a negative 
correlation. Treatment of breast cancer cells with insulin 
like growth factor-1 (IGF-1), which activated the PI3K 
pathway resulted in decreased ER expression. Likewise 
treatment of breast cancers with the PI3K inhibitor 
BEZ-235 resulted in increased ER activity as well as 
ER-regulated gene expression [197]. The PI3K pathway 
activity was increased in ER+ tumors and cell lines of the 
more aggressive luminal B subtype versus those of the less 
aggressive luminal A subtype. The PI3K inhibitor would 
increase the effects of 4HT on the more aggressive luminal 
B breast cancer, potentially by increasing ER expression 
and restoring sensitivity to hormone based therapies. 
This study suggests a potential therapeutic approach by 
combining PI3K inhibitors and 4HT.
The PI3K/PTEN/Akt/mTORC1 pathway is 
also important in the growth of breast cancers which 
have become hormone-independent. In four hormone-
independent breast cancer cell lines created after long 
term estrogen deprivation, increased phosphorylation of 
p70S6K, p85S6K and Akt was observed [198]. Inhibition 
of the PI3K pathway in these hormone-independent cells 
resulted in apoptosis. These results indicate that some 
hormone-independent breast cancers may be sensitive to 
the combination of ER and PI3K pathway inhibitors.
Inhibition of PTEN activity has been associated with 
resistance to chemotherapeutic drugs, hypersensitivity to 
the mTORC1 inhibitor rapamycin as well as hormonal 
based therapies [199,200] Inhibition of PTEN expression 
by shRNA resulted in three ERalpha+ breast cancer cell 
lines that were able to grow in the absence of hormone. 
Furthermore the cells were resistant to 4HT and 
fulvestrant. Fulvestrant is an ER antagonist that functions 
by down regulating the ER. Knock down of PTEN also 
increased ERalpha transcriptional activity in MCF-7 
cells, but decreased ER protein levels and transcriptional 
activity in T47D and MDA-361 cells. Inhibition of PTEN 
by shRNA increased basal and ligand-induced activation 
of IGF-1R and EGFR-3, documenting the effects that 
PTEN can have on the regulation of these upstream 
tyrosine kinases. Inhibition of IGF-1R or EGFR-3 restored 
hormonal dependency and the effects of hormonal therapy 
on the breast cancer cells with PTEN-knocked down. 
These studies indicate a possible treatment strategy for 
breast cancers which are either PTEN-negative or have 
decreased PTEN expression. These results document 
the complex interactions between hormonal- and growth 
factor-dependent signaling.
Association between PIK3CA Mutations and AR 
Expression in Breast Cancer. 
An association between AR expression and PIK3CA 
mutations was observed in a study which examined AR 
and ER expression and PIK3CA mutational status in 347 
breast cancer patients [201]. AR expression was higher 
in those breast cancers which also expressed ER and PR. 
In those samples that expressed AR, mutations in the 
PIK3CA kinase domain were more frequently detected 
than mutations in the helical domain or those lacking 
PIK3CA mutations. High AR expression was linked with 
an improved recurrence-free survival in 207 patients with 
early-stage ER+/PR+ positive tumors after hormonal-
based therapy. Higher AR expression was also associated 
with PIK3CA mutations and not with PIK3CA WT or 
TNBCs. These studies indicate that AR and PIK3CA (as 
well as ER and PR) may be prognostic markers for breast 
cancer [201]. 
Dysregulation of the PI3K/PTEN/Akt/mTORC1 
Pathway in Endometrial Cancer. 
Endometrial cancer is one of the most frequent 
gynecological malignancies [202]. Many signaling 
pathways have been implicated in endometriod cancer 
[203-206]. Greater than 90% of endometriod cancers 
suffer from some type of mutation in the PI3K/PTEN/Akt/
mTORC1 pathway. Thus, this pathway is a key therapeutic 
target in endometriod cancer [207,208]. Endometrioid 
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endometrial cancers (EEC) frequently have multiple 
mutations at PTEN, PIK3CA, PIK3R1 and KRAS. The 
effects of the pan-class I PI3K inhibitor GDC-0941 and the 
mTORC1 inhibitor temsirolimus were examined on EEC 
cells with concurrent PIK3CA and PTEN mutations [209]. 
ECC with PIK3CA mutations were sensitive to GDC-
0941, while ECC with PTEN mutations were sensitive to 
the mTORC1 blocker. Only 2 of 6 EEC cells with KRAS 
mutations were sensitive to MEK inhibitors. The PI3K 
p110alpha selective inhibitor A66 was more effective than 
the PI3K p110beta inhibitors GSK2636771 and AZD6482 
in suppressing the growth of the PTEN-mutant EEC cell 
lines.
Expression of the PI3K-p110 alpha and beta 
Subunits in Breast Carcinomas and EEC.
A study was performed on 315 invasive breast 
carcinomas to compare the expression of the PI3K-p110 
alpha and beta subunits in these breast cancer patients. 
Then the expression results were correlated with clinical 
outcomes [210]. This immunohistochemistry study 
determined that overall the p110 subunits were expressed 
in 23.8% of invasive breast carcinomas. PI3K-p110-alpha 
was expressed in 11.8% and 15.2% expressed PI3K-p110-
beta. This study observed that PI3K-p110-alpha expression 
was associated with hormone receptor expression but 
was not associated with overall survival. PI3K-p110-
beta expression was linked to HER2 overexpression and 
lack of hormone receptor expression. PI3K-p110-beta+ 
breast cancer patients had lower age of onset, lymph node 
involvement and distant metastasis. Those breast cancer 
patients that expressed membrane PI3K-p110-beta had 
a worse prognosis and overall survival. These important 
clinical studies point to the possibility of co-targeting 
of HER2 and PI3K-p110-beta in certain breast cancer 
patients. 
Recently it was determined that the PIK3R1 
(p85alpha) and PIK3R2 (p85beta) regulatory subunits are 
mutated in EEC [211]. PIK3R1 mutations were reported 
to occur at a higher rate in EEC than any other cancer 
type. Also this study demonstrated that the PIK3R2 gene 
is mutated in EEC, which was previously not thought to be 
a cancer gene. Many PIK3R1 and PIK3R2 mutations are 
gain of function mutations. Some PIK3R1 mutations bind 
and stabilize PTEN. KRAS mutations are also common in 
EECs. PI3K pathway mutations can occur in the presence 
of WT PTEN and they phenocopy PTEN loss as the 
pathway is activated.
Deregulation of Downstream Components of the 
PI3K/PTEN/Akt/mTORC1 Pathway Involved in 
the Regulation of mRNA Translation in Breast 
Cancer. 
The PI3K/PTEN/Akt/mTORC1 pathway serves 
to regulate the translation of certain mRNAs which are 
considered difficult to translate due to their structures. 
The PI3K/PTEN/Akt/mTORC1 pathway can regulate the 
activity of key components of the translational apparatus 
such as eIF4E, eIF4G, 4E-BP1, rpS6, programmed cell 
death protein 4 (pdcd4), eEF2 and eEF2K. The expression 
of eIF4E, eIF4G, 4E-BP1, p4E-BP1 (T37/46), p4E-
BP1 (S65), p4E-BP1 (T70), S6, pS6 (S235/236), pS6 
(S240/244), pdcd4, eEF2 and eEF2K was examined in 
190 hormone receptor-positive breast cancer patients 
[212]. This study followed the course of the breast cancer 
patients for 96 months. Elevated eEF2K, rpS6, and 
p4E-BP and decreased pdcd4 were associated with poor 
prognosis in hormone receptor+ breast cancer. These 
molecules may be prognostic markers and therapeutic 
targets for certain classes of breast cancer (e.g., hormone-
responsive breast cancers).
Involvement of GSK-3 in Breast Cancer. 
Phosphorylation by Akt also inhibits the activity 
of many key molecules involved in signaling and 
apoptosis. Activated Akt can stimulate carcinogenesis 
by inactivating proteins that normally function to limit 
cell growth and regulate apoptosis [213]. GSK-3beta 
is a down stream target of Akt. Introduction of kinase-
dead GSK-3beta [GSK-3beta(KD)] into epithelial cells 
promoted tumorigenesis of breast and skin tumors [214]. 
Overexpression of constitutively-active GSK-3beta altered 
chemosensitivity, cell cycle arrest and tumorigenicity of 
breast cancers [215-218]. Inhibition of GSK-3beta, by 
small molecule inhibitors induced epithelial mesenchymal 
transition (EMT) and invasion in breast cancer [219]. 
The localization of GSK-3beta was altered in a 
study of invasive ductal carcinomas (IDC). A reduction 
or loss of cytoplasmic GSK-3beta in was observed in 53% 
of IDC examined [220]. Nuclear accumulation of GSK-
3beta was detected in 35% of the IDC samples examined. 
This nuclear accumulation of GSK-3beta was associated 
positively with tumor grade [220]. A downstream target of 
GSK-3 is p27Kip-1 which is also implicated in breast cancer 
[221]. In addition, p70S6K can be regulated by GSK-3 
and is involved in breast cancer [222]. Figure 2 depicts 
some of the interactions with GSK-3 and these and other 
signaling molecules.
GSK-3beta and beta-catenin can regulate 
cadherin-11 post-transcriptionally in breast and prostate 
cancer cells. Inactivation of GSK-3beta lead to repression 
of cadherin-11 mRNA and protein levels [223]. Loss of 
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cytoplasmic GSK-3beta may promote EMT in breast 
cancer [223]. GSK-3 can regulate c-Myb which is 
important in EMT in breast cancer [224-227]. A studyl 
performed on breast cancer biopsies observed that 
inactivation of GSK-3beta was associated with elevated 
levels of the prolactin receptor, which is implicated in 
tumorigenesis [228]. The breast cancer resistance protein 
(BCRP) was determined to be downregulated in breast 
cancer cells when GSK-3beta was active, documenting 
that GSK-3beta can suppress active drug efflux [229]. 
Suppression of GSK-3beta activity by Akt phosphorylation 
enriched for mammary stem cells in both normal and 
breast cancer cells through activation of beta-catenin 
[230]. Thus at least with regards to mammary epithelial 
cells GSK-3beta activity appears to limit proliferation and 
suppress the stem-like cell population. 
Often GSK-3beta is thought to have roles in tumor 
suppression. However, this is not always the case. In 
certain cancer types (e.g., pancreatic cancer) GSK-3beta 
was shown to participate in pro-inflammatory and anti-
apoptotic processes by positively regulating NF-kappaB 
activity in the nucleus [231-233]. The roles of GSK-3beta 
in cancer progression remain controversial and extremely 
complex and may depend on the cancer type. The cellular 
localization of GSK-3beta is an important factor in 
controlling GSK-3beta ability to provide growth-limiting 
and survival-promoting activities. Aberrant nuclear 
accumulation of GSK-3beta may be important in many 
cancers. 
The biochemical events leading to loss of functional 
GSK-3beta activity may also enrich for a subpopulation of 
CICs that demonstrate enhanced motility, clonogenicity, 
and drug resistance. However, the production of CICs 
may depend on the cancer type as well as stage of 
differentiation. Micro RNAs (miRs) also play important 
roles in CICs. TNBCs often have a high percentage of 
CICs [234]. Different miRs are expressed in TNBC than 
other breast cancer. Breast CICs often express high levels 
of CD44 and lower levels of CD24 (CD44↑CD24↓) than 
the non-CIC population which is referred frequently to as 
the bulk cancer. Autophagy is important in the regulation 
of the CIC population [235]. GSK-3 plays important 
roles in the regulation of autophagy and other age-related 
diseases [236]. Pharmacological inhibition of GSK-3 by 
small molecule inhibitors or deletion of GSK-3alpha leads 
to the prevention of autophagy. 
We determined recently that GSK-3beta play 
important a role in MCF-7 breast cancer clonogenicity, 
drug resistance, and cell signaling [218]. Introduction of 
GSK-3beta(KD) into MCF-7 cells resulted in increases 
in both anchorage-dependent and anchorage-independent 
clonogenicity compared to cells transfected with the GSK-
3beta(WT) construct. This increase in clonogenicity was 
observed when doxorubicin was absent or present. More 
colonies were observed in MCF-7/GSK-3beta(KD) cells 
than MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) 
cells when the cells were treated with doxorubicin. MCF-
7/GSK-3beta(A9) cells with constitutive GSK-3beta 
kinase activity displayed higher anchorage-dependent, 
but not anchorage-independent, clonogenicity than MCF-
7/GSK-3beta(WT) cells. Anchorage-independent growth 
is one measurement of transformed cells. In essence, it 
measures the ability of the cells to grow without adherence 
to a tissue culture plate surface. Cells which are more 
transformed will form more colonies in soft agar than cells 
which are either “not”-tranformed or “less”-transformed. 
GSK-3beta may play multiple roles by both limiting 
proliferation under certain conditions and allowing cell 
growth in others. In some cases GSK-3beta functions as a 
tumor promoter by phosphorylation of Axin which leads 
to beta-catenin stabilization and potentially cancer. In 
contrast, other cases GSK-3beta acts as a tumor suppressor 
and induces beta-catenin phosphorylation and proteasomal 
degradation.
When the cells were plated n doxorubicin, the 
anchorage-independent colony forming ability of MCF-
7/GSK-3beta(KD) cells in doxorubicin was enhanced 
five-fold in comparison to MCF-7/GSK-3beta(WT) cells. 
Our results indicated that GSK-3beta activity influences 
breast cancer proliferation, motility and response to 
chemotherapy. Loss of GSK-3beta kinase activity may 
confer survival advantages by upregulating factors 
involved in cell cycle progression, prevention of apoptosis 
and anchorage-independence. 
Resistance to doxorubicin and 4HT was increased 
in MCF-7/GSK-3beta(KD) cells in comparison to MCF-
7/GSK-3beta(WT) cells. However, drug resistant MCF-7/
GSK-3beta(KD) cells responded to mTOR inhibition by 
treatment with rapamycin. Additionally, a combination 
treatment of consisting of a MEK inhibitor and 
doxorubicin or 4HT was determined to have a synergistic 
effect that eliminated drug resistance in MCF-7/GSK-
3beta(KD) cells. Targeting signaling molecules involved 
with the PI3K/PTEN/Akt/mTORC1 and Raf/MEK/ERK 
pathways may be appropriate to overcome resistance to 
chemo- and hormonal therapy. Genetic alterations which 
result in abnormal GSK-3beta activity should be taken 
into considered when designing a course of breast cancer 
therapy. Combination drug/inhibitor treatments could 
be advantageous by lowering the concentration of the 
chemotherapeutic drug and reduce therapy-related side 
effects.
There are alternate routes of GSK-3beta activation 
that are independent of Akt. To add to the complexity, 
GSK-3beta plays roles in the Wnt/beta-catenin pathway by 
being a component of the beta-catenin destruction complex 
as well as in the phosphorylation of Axin which results in 
the stabilization of Axin. This interaction of GSK-3 with 
the Axin protein complex prevents Akt from accessing 
and phosphorylating GSK-3beta. There are likely different 
cellular pools of GSK-3beta that are under separate 
regulation by Wnt and Akt, in which the activation of one 
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does not affect the other. Simultaneous Akt and GSK-3beta 
activity has been observed in pancreatic and colon cancer 
cell lines, indicating that increased Akt expression does 
not always result with decreased GSK-3beta activity [231]. 
Since certain pools of GSK-3beta may remain active in 
cancer, the precise cellular localization of these pools may 
also be an important factor involved in their regulation. 
GSK-3beta is thought to be active predominantly in the 
cytoplasm, but it can also translocate to the nucleus. The 
nuclear activities of GSK-3beta may appear to conflict 
with its cytosolic roles. Aberrant nuclear accumulation of 
GSK-3beta has been observed in certain cancers [231]. A 
nuclear localization signal (NLS) is present in the basic 
domain of GSK-3beta [237]. Increased translocation of 
GSK-3beta to the nucleus may be involved with cancer 
progression. 
Involvement of the Wnt Signaling Pathway 
in ERalpha+ Breast Cancers with PIK3CA 
Mutations. 
The PIK3CA gene is mutated in 30-40% of 
ERalpha+ breast cancers. Gene expression profiling of 
249 ER-alpha+ breast tumors revealed that nineteen genes 
were differently expressed in PIK3CA-mutated tumors 
in comparison to samples lacking PIK3CA mutations. 
Interesting PIK3CA mutations were associated with 
over-expression of several genes critical for the Wnt 
signaling pathway [WNT5A, transcription factor 7-like 
2 (T-cell specific, HMG-box (TCF7L2), msh homeobox 
2 (MSX2), tumor necrosis factor receptor superfamily, 
member 11b (TNFRSF11B)], as well as genes important 
in the regulation of gene transcription [SEC14-like 2 
(SEC14L2), transcription factor AP-2 beta (activating 
enhancer binding protein 2 beta) (TFAP2B), nuclear 
receptor interacting protein 3 (NRIP3)] and metal ion 
binding [cytochrome P450, family 4, subfamily Z, 
polypeptide 1 (CYP4Z1), cytochrome P450, family 4, 
subfamily Z, polypeptide 2, pseudogene (CYP4Z2P), 
solute carrier family 40 (iron-regulated transporter), 
member 1 (SLC40A1), lactotransferrin (LTF), LIM and 
calponin homology domains 1 (LIMCH1) [238]. These 
studies suggest that targeting the Wnt signaling pathway 
may be an appropriate approach to treat certain ERalpha+ 
breast cancers containing PIK3CA mutations.
Interactions between PI3K/PTEN/Akt/mTORC1 
and Raf/MEK/ERK Pathways in Breast Cancer 
and Drug Resistance. 
The Raf/MEK/ERK pathway is also important in 
breast cancer drug resistance [239,240]. The Raf/MEK/
ERK pathway often interacts with the PI3K/PTEN/Akt/
mTORC1 pathway and the two pathways often co regulate 
many signaling molecules such as p70S6K, eIF-4B, eIF-
4E, rpS6 and others. A figure illustrating some of the sites 
of targeting these pathways is present in Figure 5. A recent 
component which has been shown to be involved in breast 
cancer drug resistance is the phosphatase DUSP4 which 
removes the phosphate from active ERK1,2. Decreased 
expression of DUSP4 is associated with breast cancer 
drug resistance and increased expression of active ERK1,2 
[241]. 
Other studies have indicated that increased MAPK 
signaling is a predicator of resistance to successful 
endocrine therapy of breast cancer patients [242]. This 
study included 114 women who were ER-alpha+ that 
were randomly assigned to neoadjuvant letrozole or 
letrozole plus metronomic cyclophosphamide (frequent 
low doses of cyclophosphamide). The expression of 
twenty-four proteins involved in apoptosis, cell survival, 
hypoxia, angiogenesis and signaling were examined by 
immunohistochemistry in pretreatment samples. The 
ages, sizes of the tumors, the nodal status of the tumor, 
tumor grade, histological type and treatment were also 
followed. 81% of the patients had a disease response, 
43% achieved a complete clinical response and 19% 
did not respond. This study determined that increased 
phosphorylated ER-alpha and decreased phosphorylated 
ERK1,2 were factors associated with complete response 
to therapy. Phosphorylated and activated ER-alpha was 
an independent factor for sensitivity to chemoendocrine 
therapy. In contrast, HIF-alpha and phosphorylated 
ERK1/2 were independent factors associated with 
resistance to therapy. These and other results indicating 
that targeting ERK (e.g., with MEK inhibitors) may be 
effective in reducing the drug resistance of certain breast 
cancers.
Interactions Between Raf-1 and Aurora Kinase 
Signaling in ER+ Breast Cancer. 
Recently, it has been shown that there is a Raf-1-
mediated involvement of Aurora-A kinase signaling which 
is important in regulating the balance between EMT 
and MET in ER+ breast cancer cells. This interaction 
is also important in chemoresistance and regulating the 
expression of many genes involved in EMT and MET. The 
interactions between Raf-1 and Aurora-1 kinase signaling 
altered the metastatic potential of the cells. Constitutive 
activation of Raf-1 oncogenic signaling induced HER-
2 overexpression and resulted in the development of 
distant metastases in ERα+ MCF-7/∆Raf-1 breast cancer 
xenografts. These distant metastases in xenograft models 
were associated with activation of MET as characterized 
by reduced expression of EMT-inducer genes (TGFB2, 
TWIST1 and FOXC1) while overexpression of the BMB7, 
CXCR7 and EGR genes. Constitutive activation of Raf/
MEK/MAPK oncogenic signaling during tumor growth 
promoted the development of metastatic lesions from 
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primary tumors by activating MET [174]. 
Further studies by this same group demonstrated 
that constitutive activation of Raf-1 oncogenic signaling 
induced stabilization and accumulation of Aurora-A 
mitotic kinase. This promoted EMT and stemness in ER+ 
MCF-7/∆Raf-1 cells. The EMT transition was associated 
by reduced expression of CD24 and ERalpha, while 
HER2 and CD44 were upregulated. The upregulation 
of the stemness gene SOX2 was linked to acquisition 
of multiple stem cell-like properties. Namely the cells 
displayed an enhanced ability to form mammospheres 
in vitro and self-renewal in vivo. The aberrant Aurora-A 
kinase activity induced phosphorylation and nuclear 
translocation of SMAD5, indicating a novel interplay 
between Aurora-A and SMAD5 signaling pathways in 
the development of EMT, stemness and ultimately tumor 
progression. Pharmacological and molecular inhibition of 
Aurora-A kinase activity restored the CD24↑ epithelial 
phenotype that was coupled with ERalpha expression, 
downregulation of HER2, inhibition of EMT and impaired 
self-renewal ability and suppression of distant metastases. 
These findings demonstrated the importance of Aurora-A 
kinase in the activation of EMT pathway responsible for 
the development of distant metastases in ERalpha+ breast 
cancer cells. This study has translational implications 
because it highlighted the mitotic kinase Aurora-A as a 
novel, promising therapeutic target to eliminate invasive 
breast cancer cells and improve the disease-free and 
overall survival of ERalpha+ breast cancer patients 
resistant to conventional endocrine therapy [164]. 
Further studies indicated that cross-talk between 
ERalpha+ and Raf/MEK/ERK signaling pathways is a 
key oncogenic axis which is responsible in part for the 
development of ER-independent growth of breast cancers 
which were initially ERalpha+ and hormone sensitive. 
In a metastatic breast cancer xenograft model harboring 
constitutive activation of Raf-1, the link between aberrant 
Raf/MEK/ERK signaling and development of endocrine 
resistance through abrogation of the ERα signaling 
axis was elucidated. The Aurora-A mitotic kinase was 
demonstrated to be important in the development of 
endocrine resistance. Activation of SMAD5 nuclear 
signaling was detected as well as down-regulation of 
ERalpha. These results suggest that the development 
of novel molecular therapies targeting the Aurora-A/
SMAD5 oncogenic axis may be beneficial for the selective 
eradication of endocrine resistant ERalpha- cancer cells 
from the bulk tumor with benefits for breast cancer 
patients [243]. 
Relationship between Raf-1/p53/Aurora Kinase 
and Centrosome Amplification in Breast Cancer. 
Centrosome amplification has been shown to 
play key roles in the origin of chromosomal instability 
(CIN) that affects cancer development and progression. 
The relationships between induction of genotoxic 
stress, activation of cyclin-A/Cdk2 and Aurora-A 
and development of centrosome amplification were 
investigated in MCF-7 breast cancer cell lines harboring a 
dominant negative (DN) p53 mutation (vMCF-7DNp53). 
Genotoxic stress was induced in the MCF-7 cells 
harboring the DN p53 by treatment with hydroxyurea 
(HU) which induced centrosome amplification. Aurora-A 
kinase activity was linked with centrosome amplication. 
The Aurora-A kinase-induced centrosome amplification 
was determined to be mediated by Cdk2 kinase. Molecular 
inhibition of Cdk2 activity by SU9516 suppressed 
Aurora-A centrosomal localization and consequent 
centrosome amplification. MCF-7 cells harboring 
constitutively-activated Raf-1 displayed high levels of 
endogenous cyclin-A. Targeting of Aurora-A by the Aurora 
kinase inhibitor Alisertib reduced cyclin-A expression. 
Thus there is a positive feed-back loop between cyclin-A/
Cdk2 and Aurora-A pathways in the development of 
centrosome amplification in breast cancer cells which 
may be which may provide additional approaches to target 
drug resistant breast cancer patients [244]. These studies 
document the key interactions between the Raf/MEK/ERK 
and Aurora kinase pathways which may be important in 
regulating breast cancer progression and serve as targets 
for therapeutic intervention.
Breast Cancer Therapy. 
The most commonly utilized treatment for breast 
cancer is surgical resection with adjuvant chemotherapy, 
hormone therapy or radiation (National Cancer Institute, 
2013). Radiation and chemotherapy are effective in killing 
or limiting the growth of actively dividing cancer cells 
through various mechanisms including the production 
of oxygen free radicals, DNA damage, and subsequent 
apoptosis [245-251]. Common chemotherapeutic drugs 
used to treat breast cancer include the anthracyclines, 
taxanes, 5-fluorouracil, cyclophosphamide, and 
methotrexate [252]. Doxorubicin, also known as 
adriamycin, is in the anthracycline class of antibiotic 
chemotherapeutic drugs. These compounds work by 
intercalating between adjacent DNA base pairs and 
inhibiting topoisomerase II, thereby interfering with DNA, 
RNA, and protein synthesis. 
The effects of combining chemotherapeutic drugs 
have been analyzed by clinical trials. 
A phase III, clinical trial with 1491 patients with 
node-positive, early breast cancer were randomly assigned 
to adjuvant treatment with docetaxel, doxorubicin, and 
cyclophosphamide (ACT) or fluorouracil, doxorubicin, 
and cyclophosphamide (FAC) every 3 weeks for six 
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cycles. The 10 year follow-up analysis of disease-free 
survival, overall survival, and long-term safety in the 
clinical trial was reported [253]. In general, breast cancer 
patients in ACT treatment group had better disease-free 
survival relative to breast cancer patients in the FAC 
treatment group. In this study, hormone receptor, and 
HER2 status and nodal involvement status did not appear 
to change the disease-free survival between the enhanced 
survival in ACT treatment group vs. the FAC treatment 
group. This study also documented that there were a 
significant percentage of patients who had a decrease in 
ventricular ejections secondary to anthracycline therapy.
An additional study evaluated the effects of ACT 
and FAC treatments on node negative breast cancer 
patients over a 5 year observation period. This study 
was performed as it was known previously that ACT 
is superior to FAC when used as adjuvant therapy in 
women with node-positive breast cancer but the effects 
of taxanes on breast cancer patients with node cancer 
were not known [254]. The breast cancer patients in the 
two treatment groups were examined for 77 months. The 
disease-free survival was higher in the ACT group (87.8%) 
than the FAC group (81.8%). Thus the ACT treatment may 
be appropriate for some high risk, lymph node negative 
breast cancer patients.
Hormonal Therapy Combined with mTORC1 
Blockage.
Another common treatment option for breast cancer 
consists of a hormonal-based approach [255]. Many early 
stage breast cancers overexpress various isoforms of the 
ER, making their growth dependent on estrogen. 4HT is a 
selective ER modulator. 4HT can block estrogen signaling 
by competitively binding the ER and antagonizing its 
proliferative effects [256]. Once a breast cancer has 
undergone additional molecular changes allowing it to 
overcome estrogen-dependence, hormonal therapy is no 
longer effective, however, certain inhibitors can reverse 
the estrogen-independence (see Figures 3 and 4) [257-
261]. 
Exemestane is an AI and prevents conversion of 
testosterone into estrogen. The quality of life was observed 
to be better in hormone-responsive metastatic breast 
cancer patients treated with exemestane and the mTORC1 
blocker everolimus than patients treated with exemestane 
by itself. In the BOLERO-3 study with herceptin-
resistant metastatic breast cancer patients, treatment with 
everolimus, herceptin and vinorelbine was more effective 
than treatment of with herceptin and vinorelbine [262]. 
Vinorelbine (Navelbine) is anti-mitotic drug [261]. It is 
used to treat non-small cell lung cancer and metastatic 
breast cancer. Thus suppressing mTORC1 activity could 
enhance the effectiveness of exemestane and Herceptin in 
different types of breast cancer patients. 
Previously it was thought that hormonal therapy 
would only be effective in treatment of breast cancer 
cells which express ER-alpha. Triple negative breast and 
HER2+ cancers often do not expresses ER-alpha, but some 
express ER-beta and may be sensitive to hormonal therapy 
[262]. The expression of hormonal receptors (ER, PR) and 
HER2 may change with the progression of breast cancer 
into metastatic cancer. In addition, the combination of 
hormonal based therapy can be enhanced by the addition 
of herceptin and mTORC1 blockers in some cases.
Figure 2: Dysregulated Expression of Upstream 
Receptors and Kinases Can Result in Activation of 
the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/
mTOR and Other Signaling Pathways and Contribute 
to Malignant Transformation. Sometimes dysregulated 
expression of growth factor receptors occurs by increased 
expression, genetic translocations or genomic amplifications 
which can lead to activation of the Ras/Raf/MEK/ERK, 
Ras/PI3K/PTEN/Akt/mTOR and other signaling pathways. 
Alternatively chromosomal translocations can occur in non-
receptor kinases and other genes which result in activation of 
these pathways. Genes in the Ras/Raf/MEK/ERK and Ras/PI3K/
PTEN/Akt/mTOR pathways that have activating mutations 
detected in human cancer and proliferative diseases are indicated 
in red ovals and squares. Tumor suppressor genes inactivated in 
certain cancer are indicated in black squares or octagons. Other 
key genes are indicated in green ovals. Red arrows indicate 
activating events in pathways. Blocked black arrows indicating 
inactivating events in pathways. 
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Antibody Therapy of Breast Cancer.
The genetically engineered antibody herceptin 
(trastuzumab) is used to treat HER2+ breast cancers. 
Combining herceptin with chemotherapy increases 
survival and response rates [263]. However a significant 
problem with chemotherapy is cardiotoxicity. Herceptin 
therapy is also expensive and not always covered by 
insurance companies [264]. A diagram depicting the 
targeting of HER2 and other signaling molecules and sites 
where herceptin-resistance occurs is presented in Figure 6.
Pertuzumab (Perjeta(®) is a newer antibody 
developed by Genentech/Roche. Pertuzumab and 
herceptin binding to different sites on HER2 and the 
combined administration of pertuzumab and herceptin 
had synergistic inhibitory effects on HER2+ breast cancers 
[265]. 
Pertuzumab prevents the dimerization of HER2 with 
other EGFR family members (EGFR1, EGFR3, EGFR4) 
[266]. Pertuzumab prevents the interaction of HER2 with 
EGFR3 and subsequent activation of the PI3K/PTEN/
Akt/mTOR pathway. This has been proposed to be in part 
responsible to the anti-cancer effects of pertuzumab [267].
Initial studies with just pertuzumab did not 
reveal impressive results in suppressing cancer growth. 
However, in the more recent phase III CLEOPATA trial 
have revealed that combination of pertuzumab with 
herceptin and docetaxel were promising and significantly 
improved prolonged progression-free survival for a 
first-line treatment of HER2+ metastatic breast cancer 
and importantly no increase in cardio-toxic effects were 
observed [268]. Pertuzumab received approval by the FDA 
to treat HER2+ metastatic breast cancer patients in 2012. 
Pertuzumab in combination with herceptin and a taxol has 
been approved by the FDA and is being evaluated as a first 
line treatment option for HER2+ metastatic breast cancer 
patients who have not been previously treated with anti-
HER2 therapy or chemotherapy [269]. 
Pertuzumab is being further evaluated in the 
following clinical trials: MARIANNE, for advanced 
breast cancer, NEOSPHERE, for early breast cancer, 
TRYPAHENA, for HER2+ stage II/III breast cancer and 
APHINITY for HER2+ nonmetastatic breast cancer [270]. 
Figure 3: Effects of Targeting PI3K/PTEN/Akt/mTORC1 and IL-6 on Breast Cancer Hormonal Dependency, EMT 
and CICs. Mutations at PIK3CA can alter hormonal dependency. Silencing PI3K with PI3K inhibitors can restore hormonal dependency. 
Silencing PTEN can also result in hormonal-independenc, 4HT and fulvestrant resistance. Silencing PTEN can in some cases also lead in 
some cases to IL-6 production and an IL-6 inflammatory feed back loop which results in EMT and CIC formation. Silencing of IL-6 with 
monoclonal antibodies (MoAb) can prevent this loop and result in the death of the breast CICs.
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Trastuzumab emtansine is an antibody-drug 
modification of herceptin which is now linked with the 
cytotoxic agent mertansine (DM1). It is abbreviated 
T-DM1 (trastuzumab-DM1) and also called Kadcyla, 
ado-trastuzumab emtansine and PRO132365. Mertansine 
inhibits cell growth by binding to tubulin [271]. Herceptin 
targets the antibody-drug conjugate to HER+ cells [272]. 
T-DM1 is more effective than Herceptin in the treatment of 
HER+ advanced metastatic breast cancer patients. It was 
evaluated in the EMILIA phase III clinical trial. This trial 
consisted of 991 cancer patients with unrectable, locally 
advanced or metastatic HER+ breast cancer which had 
been previously treated with herceptin and taxanes with 
breast cancer patients treated with capecitabine (Xeloda) 
plus lapatinib (Tykerb). Progression free survival was 
enhanced in breast cancer patients treated with T-DM1. 
It has been approved by the FDA for the treatment of 
HER2+ advanced metastatic breast cancer patients. 
T-DM1 has also been evaluated in other clinical trials 
such as MARIANNE, which compares the effectiveness 
of the taxanes (docetaxel or paclitaxel) combined with 
Herceptin vs T-DM1 by itself vs T-DM1 plus pertuzumab 
as a first line therapy for HER2+ breast cancers. Patients 
in this study are HER2+, which have either unresectable 
locally advanced or metastatic breast cancer. T-DM1 is 
also being investigated in the TH3RESA clinical trial 
which is evaluating the effectiveness T-DM1 in HER2+ 
metastatic breast cancer patients that were previously 
treated with Herceptin and the EGFR2 kinase inhibitor 
lapatinib. T-DM1 is also being evaluated in gastric cancers 
in clinical trials. Tables 1-3 and Supplementary Tables 1-3 
list the various clinical trials in breast cancer which are 
listed on the ClinicalTrial.gov website.
EGFR, PI3K, and mTORC1 inhibitors are being 
evaluated to treat breast cancer patients. Drug targeting the 
ER have been developed and many have been evaluated in 
clinical trials [273]. The ER modulators: 4HT, raloxifene, 
and lasofoxifene) and AIs (anastrozole, letrozole, and 
exemestane) have been evaluated extensively [273]. An 
important pitfall with these drugs is they were thought to 
be only effective in ER+ cancers. Drugs such as herceptin 
are more effective on HER2+ breast cancers.
Lapatinib is a small molecule HER2/EGFR1 
dual kinase inhibitor that has also shown be effective in 
inhibiting the growth of HER2+ breast cancers. TNBCs 
do not express either ER or HER2, thus novel therapies 
Figure 4: Effects of PI3K/PTEN/Akt/mTORC1 on Aromatase Resistance and Sensitivity to Tamoxifen (4HT). The 
aromatase inhibitor (AI) letrozole prevents the conversion of testosterone (TEST) into estrogen (ER) and hence there is no ERalpha 
mediated gene transcription. Letrozole alters the expression of the PI3K/PTEN/Akt/mTORC1 pathway. PI3K inhibitors will restore 
ERalpha mediated gene expression in Letrozole resistant cells and the cells revert to hormonal sensitivity. Likewise PI3K inhibitors will 
restore the sensitivity of 4HT-resistant cells to 4HT. Breast cells with mutations at PIK3CA may develop resistance to 4HT and PI3K 
inhibitors may restore sensitivity to 4HT. 
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need to be developed for this class of breast cancer. Drugs 
being evaluated to treat TNBC include poly ADP-ribose 
polymerase (PARP) inhibitors, vitamin D, and rexinoids, 
which activate the vitamin D and retinoid X receptors. 
Mechanisms of Lapatinib-Resistance in HER2+ 
Cells: Activation of PI3K and Src.
The PI3K pathway and Src activation may be 
a mechanism by which some HER2+ cells grow in 
response to HER2 inhibition by treatment with small 
molecule HER2 inhibitors such as lapatinib. Lapatinib-
resistant HER2+ breast cancer cell lines were generated 
by culturing the cells in the presence of lapatinib for 
prolonged periods of time. These cells did not express 
activated HER2, but they did express the PI3K/PTEN/Akt/
mTORC and Raf/MEK/ERK pathways which is believed 
to be due to activated Src family members. Treatment of 
the lapatinib-resistant HER2+ cells with Src inhibitors 
suppressed the PI3K/PTEN/Akt/mTOR pathway as well as 
Figure 5: Sites of Targeting the EGFR/PI3K/PTEN/Akt/mTORC Pathway with Small Molecule Membrane-Permeable 
Inhibitors and Monoclonal Antibodies (MoAbs). The PI3K/PTEN/Akt/mTORC1 pathway is regulated by Ras (indicated in green 
ovals), as well as various upstream growth factor receptors (indicated in purple) and PTEN indicated in a black rectangle. Sites where 
various small molecule inhibitors suppress this pathway are indicated by red octagons. The downstream transcription factors regulated by 
this pathway are indicated in yellow diamond shaped outlines. The Ras/Raf/MEK/ERK pathway also interacts with key proteins involved 
in protein translation (indicated in green ovals). The two pathways aid in the assembly of the protein translation complex (indicated in 
purple ovals) responsible for the translation of “weak” mRNAs (indicated in a red line folding over on itself) important in the prevention 
of apoptosis. Other key proteins inactivated by PI3K/PTEN/Akt/mTORC1 pathway (e.g., TSC, PTEN, beta-catenin, Foxo and 4E-BP1 are 
indicated by black ovals, diamonds and rectangles. Red arrows indicate activating events in pathways. Blocked black arrows indicating 
inactivating events in pathways. GF = growth factor, GFR = growth factor receptor.
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Figure 6: Sites of Resistance in the HER2/PI3K/PTEN/Akt/mTORC Pathway and Potential Sites for Intervention 
with Small Molecule Membrane-Permeable Inhibitors and Monoclonal Antibodies (MoAbs). The HER2/EGFR receptor 
is indicated in a blue figure. The downstream PI3K/PTEN/Akt/mTORC1 pathway is regulated by Ras (indicated in green ovals), PTEN 
indicated in a black octagon, activated Src is indicated by a red oval, IRS1 is indicated by an orange oval. Sites where various small 
molecule inhibitors suppress this pathway are indicated by red octagons. Sites which stimulate proteins involved in autophagy are indicated 
by green octagons and ovals. The Serine/threonine-protein kinase ULK1 (ULK1) which is regulated by mTORC1 is indicated in a black 
oval. The downstream transcription factors regulated by this pathway are indicated in yellow diamond shaped outlines. The Ras/Raf/
MEK/ERK pathway also interacts with key proteins involved in protein translation (indicated in green ovals). The two pathways aid in the 
assembly of the protein translation complex (indicated in purple ovals) responsible for the translation of “weak” mRNAs (indicated in a red 
line folding over on itself) important in the prevention of apoptosis. Other key proteins inactivated by PI3K/PTEN/Akt/mTORC1 pathway 
(e.g., TSC, PTEN, GSK-3beta, beta-catenin, Foxo and 4E-BP1 are indicated by black ovals, diamonds and rectangles. Red arrows indicate 
activating events in pathways. Blocked black arrows indicating inactivating events in pathways. 
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Table 1: Clinical Trials with Single Targeted Agent Treatments (Monotherapy)
Official Trial Name Clinical Trial # Phase of Trial Type of Cancer Patient in Trial Status of Trial Intervention Publications
Phase II Trial of Akt Inhibitor 
MK2206 in Patients With Advanced 
Breast Cancer Who Have Tumors 
With a PIK3CA Mutation, or an AKT 
Mutation, and/or PTEN Loss/PTEN 
Mutation
NCT01277757
II
Male Breast Cancer (BC), recurrent 
BC, stage IIIB BC, stage IIIC BC, 
stage IV BC
Recruiting  MK2206Akt inhibitor
Not
Provided 
Pre-surgical Evaluation of MK-2206 
in Patients With Operable Invasive 
Breast Cancer
NCT01319539 II
ER- BC,  ER+ BC, HER2- BC, 
HER2+ BC, PR- BC, PR+ BC, stage 
IB BC, stage II BC, stage IIIA BC, 
stage IIIB BC, stage IIIC BC, TNBC
Ongoing, but 
not recruiting 
participants
MK2206 Not
provided
A Phase I, Open-Label, Two-Stage 
Study to Investigate the Safety, 
Tolerability, Pharmacokinetics and 
Pharmacodynamics of the Oral AKT 
Inhibitor GSK2141795 in Subjects 
With Solid Tumors or Lymphomas
NCT00920257 I Cancer Completed GSK2141795Akt Inhibitor
Not
 provided
A Phase II Trial of BKM120 (a PI3K 
Inhibitor) in Patients With Triple 
Negative Metastatic Breast Cancer
NCT01629615 II BC
Currently 
recruiting 
participants
BKM120
PI3K Inhibitor
Not 
provided 
A Phase I/II, Multi-center, Open-
label Study of BEZ235, Administered 
Orally on a Continuous Daily 
Dosing Schedule in Adult Patients 
With Advanced Solid Malignancies 
Including Patients With Advanced 
Breast Cancer
NCT00620594 I
BC, Advanced Solid Tumors, Cowden 
Syndrome Completed
 BEZ235
PI3K/mTOR 
Inhibitor
Not 
provided
A Phase II Trial of Short-Term 
Everolimus (RAD001) to Predict 
Response in Women With Operable 
Breast Cancer
NCT00855114 II BC Withdrawn
Everolimus 
(mTORC1 
blocker) 
Not 
provided
Phase II Trial of CCI-779 
(Temsirolimus) in Patients With 
Locally Advanced or Metastatic 
Breast Cancer
NCT00376688 II Male BC, Recurrent BC, Stage IIIA, Stage IIIB, Stage IIIC, Stage IV BC
Ongoing but 
not recruiting
Temsirolimus 
(mTORC1 
blocker)
Not 
provided
A Phase Ib/II Study Investigating 
the Combination of Everolimus 
With Trastuzumab and Paclitaxel in 
Patients With HER2-overexpressing 
Metastatic Breast Cancer
NCT00426556 I
Metastatic BC Completed Everolimus Not provided
A Phase II Trial of RAD001 in Triple 
Negative Metastatic Breast Cancer NCT00827567 II Breast cancer Terminated
RAD 001
(everolimus) [337-339]
A Phase Ib Study Investigating the 
Combination of Everolimus With 
Trastuzumab and Vinorelbine in 
Patients With HER2-overexpressing 
Metastatic Breast Cancer
NCT00426530 I
Breast Neoplasms, Neoplasm 
Metastasis Completed Everolimus [340] 
Neoadjuvant Phase II Study Of 
Everolimus Plus Cisplatin In Triple 
Negative Breast Cancer Patients 
With Residual Disease After Standard 
Chemotherapy
NCT01931163 II
BC, TNBC Recruiting Everolimus Not provided
Randomized, Double Blind, 
Multicentric Phase III Trial 
Evaluating the Safety and Benefit 
of Adding Everolimus to Adjuvant 
Hormone Therapy in Women With 
Poor Prognosis, ER+ and HER2- 
Primary Breast Cancer Who Remain 
Free of Disease After Receiving 3 
Years of Adjuvant Hormone Therapy
NCT01805271 III
ER+, HER2- BC Recruiting Everolimus Not provided
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RADAR: A Randomized 
Discontinuation Phase II Study to 
Determine the Efficacy of RAD001 
in Breast Cancer Patients With Bone 
Metastases
NCT00466102 II BC
Ongoing, but 
not recruiting
RAD001 Not 
provided
Phase II Trial of RAD001 Plus 
Carboplatin in Patients With Triple-
Negative Metastatic Breast Cancer NCT01127763
II BC Ongoing, but not recruiting RAD001
Not 
provided
A Randomized Phase II Study of Two 
Different Schedules of RAD001C in 
Patients With Recurrent/Metastatic 
Breast Cancer
NCT00255788 II BC Completed Everolimus
Not 
provided
A Randomized Study of mTOR 
Inhibition by RAD001 (Everolimus) 
in Invasive Breast Cancer Patients 
After Pre-operative Use of 
Anthracycline and/or Taxane-based 
Chemotherapy
NCT01088893 II
BC
Unknown 
because 
information 
has not been 
verified 
recently
Everolimus Not provided
A Multicenter Randomized, Double 
Blind, Placebo- Controlled, Phase 
II Study to Compare Endocrine 
Treatment Alone Versus Endocrine 
Treatment With Everolimus in 
Patients With HR+/HER2- Metastatic 
Breast Cancer and Progression After 
Previous Treatment With Exemestane 
and Everolimus
NCT01773460 III Metastatic BC Recruiting Everolimus
Not 
provided
Influence of Exceptional Patient 
Characteristics on Everolimus 
Exposure NCT01948960
IV BC Recruiting Everolimus Not provided
A Phase Ib Study Administering 
Rapamycin (Sirolimus) With 
Grapefruit Juice in Patients With 
Advanced Malignancies
NCT00375245 I Tumors,  Neoplasm Metastasis Completed
Rapamycin 
(sirolimus) 
Other: 
Grapefruit 
Juice
Not 
provided
A Phase Ib, Open-label Study to 
Evaluate RAD001 as Monotherapy 
Treatment in Chinese Patients 
With Advanced Pulmonary 
Neuroendocrine Tumor
NCT01175096 I/II
Neuroendocrine Tumors,  Carcinoid 
Tumor
Recruitment 
unknown 
because 
information 
has not been 
verified 
recently
RAD001 
(everolimus, 
Afinitor®)
Not 
provided
A Phase 1/2, Multi-Center, Open-
Label, Dose Finding Study to 
Assess the Safety, Tolerability, 
Pharmacokinetics and Preliminary 
Efficacy of the mTOR Kinase 
Inhibitor CC-223 Administered 
Orally to Subjects With Advanced 
Solid Tumors, Non-Hodgkin 
Lymphoma or Multiple Myeloma. 
NCT01177397 I/II
Multiple Myeloma, Diffuse Large 
B-Cell Lymphoma, Glioblastoma 
Multiforme, Hepatocellular 
Carcinoma, Non-Small Cell Lung 
Cancer, Neuroendocrine Tumors of 
Non-Pancreatic Origin, Hormone 
Receptor-Positive BC
Currently 
recruiting 
participants
CC-223 Not provided
A Randomized Study of mTOR 
Inhibition by RAD001 (Everolimus) 
in Invasive Breast Cancer Patients 
After Pre-operative Use of 
Anthracycline and/or Taxane-based 
Chemotherapy
NCT01088893 II BC
Recruitment 
unknown 
because the 
information 
has not been 
verified 
recently
Everolimus Not provided
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growth and restored sensitivity to lapatinib. Treatment of 
primary HER2+ tumors with lapatinib actually resulted in 
the expression of Src-family kinases as detected by mRNA 
analysis. Treatment of HER2+ BT-474 cells with lapatinib 
and Src inhibitors was more effective in suppressing the 
growth of these cells in xenograft models than treatment 
with lapatinib alone. These studies provide a rationale for 
the treatment of certain HER2+ cells with the combination 
of lapatinib and Src inhibitors as a means to prevent drug 
resistance of HER2+ cells [274]. Thus activation of Src 
family kinases may be a mechanism by which some 
HER2+ cells become resistant to HER2 inhibitors such 
as lapatinib.
Cotargeting of mTORC1 and Other Signaling 
Pathways in Breast Cancer Therapy. 
The possibility of targeting mTORC1 and other 
signaling pathways such as Raf/MEK/ERK, PI3K, IGF-
1R to treat breast cancer is also being examined [275]. In 
some cases, treatment with rapalogs induces the IGF-1R 
or PDGFR pathways which in turn will activate the Raf/
MEK/ERK pathway. This type of approach may also be 
appropriate to over come the rapamycin-resistance that 
certain breast cancers have developed. There are clinical 
trials in progress evaluating the effectiveness of co 
targeting mTORC1 and pathways such as IGF-1R, PI3K 
Table 2: Combined Targeted Agent Treatments
Official Trial Name Clinical Trial # Phase of Trial Type of Cancer Patient in Trial Status of Trial Intervention Publications
An Open-Label, Two Part, 
Phase I/II Study to Investigate 
the Safety, Pharmacokinetics, 
Pharmacodynamics, and 
Clinical Activity of the MEK 
Inhibitor GSK1120212 in 
Combination With the AKT 
Inhibitor GSK2110183 in 
Subjects With Solid Tumors 
and Multiple Myeloma
NCT01476137 I Cancer Completed
GSK1120212,
GSK2110183
Not 
provided
A Phase Ib, Open-label, 
Multi-center, Dose-escalation 
and Expansion Study of 
an Orally Administered 
Combination of BKM120 
Plus MEK162 in Adult 
Patients With Selected 
Advanced Solid Tumors
NCT01363232 I
Advanced Solid Tumors,  Selected Solid 
Tumors
Ongoing, 
but not 
participating
BKM120 (a 
pan-class I PI3K 
inhibitor)+ 
MEK162 (MEK 
inhibitor)
Not 
provided
A Phase Ib, Open-label, 
Multi-center, Dose-escalation 
Study of Oral BKM120 
in Combination With Oral 
GSK1120212 in Adult 
Patients With Selected 
Advanced Solid Tumors.
NCT01155453 I
Advanced Solid Tumors, Selected Solid 
Tumors Ongoing, but not recruiting
BKM120, 
GSK1120212
Not 
provided
A Phase I/II Trial of an 
Oral MTOR Protein Kinase 
Inhibitor (Everolimus, 
RAD001) in Combination 
With an Oral EGFR Tyrosine 
Kinase Inhibitor (Erlotinib, 
Tarceva™) In Patients With 
Metastatic Breast Cancer
NCT00574366 I BC Completed
Erlotinib (EGFR1 
inhibitor), 
Everolimus 
(RAD001)
Not 
provided
An Open-label, Multi-center 
Phase I Dose-finding Study 
of RAD001 (Everolimus, 
Afinitor®) in Combination 
With BEZ235 in Patients 
With Advanced Solid Tumors
NCT01482156 I
Advanced Solid Tumors, Metastatic BC, 
Metastatic Renal Cell Carcinoma Ongoing, but not recruiting
RAD001 + 
BEZ235, a dual 
inhibitor of PI3K 
and mTOR
Not 
provided
Phase I/II Trial of IMC-A12 
in Combination With 
Temsirolimus in Patients With 
Metastatic Breast Cancer
NCT00699491 I/II
Male BC, Recurrent BC, Stage IV BC Ongoing, but 
not recruiting
Cixutumumab 
(an IGF-1R 
inhibitor), 
temsirolimus 
Not 
provided
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Phase I Clinical Trial of 
Temsirolimus and Vinorelbine 
in Advanced Solid Tumors. NCT01155258 I
Extensive Stage Small Cell Lung 
Cancer, Hereditary Paraganglioma, 
Male BC, Malignant Paraganglioma, 
Metastatic Gastrointestinal Carcinoid 
Tumor, Metastatic Pheochromocytoma, 
Pancreatic Polypeptide Tumor, 
Recurrent Breast Cancer, Recurrent 
Cervical Cancer, Recurrent Endometrial 
Carcinoma, Recurrent Gastrointestinal 
Carcinoid Tumor, Recurrent Islet Cell 
Carcinoma Recurrent Neuroendocrine 
Carcinoma of the Skin, Recurrent Non-
small Cell Lung Cancer, Recurrent 
Ovarian Epithelial Cancer Recurrent 
Ovarian Germ Cell Tumor, Recurrent 
Pheochromocytoma, -Recurrent Prostate 
Cancer, Recurrent Renal Cell Cancer, 
Recurrent Small Cell Lung Cancer, 
Recurrent Uterine Sarcoma, Regional 
Gastrointestinal Carcinoid Tumor, 
Regional Pheochromocytoma, Stage III 
Cervical Cancer, Stage III Endometrial 
Carcinoma, Stage III Neuroendocrine 
Carcinoma of the Skin, Stage III Ovarian 
Epithelial Cancer, Stage III Ovarian 
Germ Cell Tumor, Stage III Prostate 
Cancer, Stage III Renal Cell Cancer, 
Stage III Uterine Sarcoma, Stage IIIA 
BC, Stage IIIA Non-small Cell Lung 
Cancer, Stage IIIB BC, Stage IIIB Non-
small Cell Lung Cancer, Stage IIIC BC, 
Stage IV BC, Stage IV Endometrial 
Carcinoma,  Stage IV Neuroendocrine 
Carcinoma of the Skin, Stage IV Non-
small Cell Lung Cancer, Stage IV 
Ovarian Epithelial Cancer, Stage IV 
Ovarian Germ Cell Tumor, Stage IV 
Prostate Cancer, Stage IV Renal Cell 
Cancer, Stage IV Uterine Sarcoma, 
Stage IVA Cervical Cancer, Stage 
IVB Cervical Cancer Thyroid Gland 
Medullary Carcinoma
Ongoing, but 
not recruiting
Temsirolimus, 
vinorelbine 
ditartrate (an 
anti-mitotic vinca 
alkaloid)
Not 
provided
A Phase I Study of 
Temsirolimus in Combination 
With Metformin in Advanced 
Solid Tumours NCT00659568
I
BC, Endometrial Cancer, Kidney Cancer 
Lung Cancer, Lymphoma, Unspecified 
Adult Solid Tumor, Protocol Specific
Completed
Metformin 
hydrochloride, 
temsirolimus
Not 
provided
An Open-Label, Phase Ib 
Dose Escalation Trial of 
Oral Combination Therapy 
With MSC1936369B and 
SAR245409 in Subjects 
With Locally Advanced or 
Metastatic Solid Tumors
NCT01390818 I
Locally Advanced Solid Tumor, 
Metastatic Solid Tumor, BC, Non Small 
Cell Lung Cancer, Melanoma, Colorectal 
Cancer
Ongoing, but 
not recruiting
MSC1936369B  
(a MEK 
inhibitor) and 
SAR245409 (a 
dual PI3K/mTOR 
inhibitor)
Not 
provided
A Phase I Study of BKM120 
and Everolimus in Advanced 
Solid Malignancies NCT01470209
I Solid Tumors Recruiting participants
BKM120, 
everolimus
Not 
provided
A Phase Ib, Open-label, 
Multi-center, Dose-escalation 
and Expansion Study of 
an Orally Administered 
Combination of BEZ235 Plus 
MEK162 in Adult Patients 
With Selected Advanced Solid 
Tumors
NCT01337765 I
Unspecified Adult Solid Tumor, Protocol 
Specific Solid Tumor
Completed BEZ235,  MEK162
Not 
provided
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and Raf/MEK/ERK (find out how many trials). 
Combinations of Herceptin with pertuzumab, or 
T-DM1 and mTOR inhibitors added to an aromatase 
inhibitor are new therapeutic approaches for the treatment 
of HER2+ breast cancers [276].
Inhibition of mTORC1 in combination with 
endocrine therapy may be an approach for treatment of 
metastatic breast cancer patients which are resistant to 
aromatase in inhibitors. Two clinical trials (TAMRAD and 
BOLERO-2) have revealed significant effects [277]. 
Combining Herceptin with PI3K, mTORC1 
Inhibitors or Chemotherapy to Improve Breast 
Cancer Therapy.
Recently it was demonstrated that combining a pan 
PI3K inhibitor (XL 147) with Herceptin may overcome 
herceptin-resistance in breast cancer by suppressing 
HER2/PI3K/FOXO/survivin signaling [278]. 
Clinical trials have been performed examining the 
ability to combine lapatinib, herceptin with paclitaxel 
in first line HER2+ positive breast cancer patients. The 
dose limiting toxicity observed in the study was diarrhea 
[279]. Clinical studies examining the combination of 
the mTORC1 blocker everolimus and either 4HT or 
exemestane (Aromasin) have been reviewed [280]. 
Previous clinical studies combining endocrine therapy 
with rapalogs to treat metastatic hormone receptor+ breast 
cancer patients yielded variable results. However, two 
recent independent trials which selected patients refractory 
to endocrine therapy, demonstrated that combining the 
rapalog everolimus (Afinitor) with 4HT or combining 
everolimus with exemestane (Aromasin) was more 
effective than either endocrine agent alone. The rapalogs 
may sensitize the normally endocrine therapy resistant 
patients to endocrine therapy. Likewise additional clinical 
trials with HER2+ breast cancer patients and the inclusion 
of PI3K/mTOR inhibitors may improve therapy of the 
HER2 inhibitors. 
Novel Approaches to Treat TNBC Patients. 
While therapies for ER+ and HER+ breast cancer 
patients have improved over the years, the treatment 
possibilities for TNBC are more limited. A recent review 
has summarized the clinical results with more novel 
approaches to treat TNBCs which include inhibitors 
of enzymes such as PARP and HDAC, kinases such as 
Jak2 and Src and receptor kinases as well as biological 
processes such as angiogenesis [281]. 
Resistance to Therapy.
Rb is a critical protein involved in the regulation 
of cell cycle progression and is a tumor suppressor. The 
Rb pathway is involved in sensitivity to tamoxifen. Loss 
of functional Rb activity is associated with resistance 
to tamoxifen [282,284]. Thus oncogenes and tumor 
suppressor genes often are important in the sensitivity to 
therapy [168,285]. A diagram depicting some of the sites 
where mutations result in resistance to therapy is presented 
in Figure 7. Breast cancers can be inherently drug 
resistance or develop an acquired resistance after exposure 
to the particular drug [213,252]. Resistance can develop 
in patients and breast cancer cells when treated with 
anthracycline chemotherapy drugs, such as doxorubicin, 
daunorubicin, and epirubicin as well as hormonal based 
therapies [199,285,286]. Therefore, cancer cells are 
capable of undergoing calculated changes that confer 
survival advantages in otherwise nutrient-restricted or 
toxic environments [287,288]. Thus novel targets and 
approaches to treat breast cancer are being evaluated 
[167,289-308]. TGF-beta and Smads are also important 
targets in breast cancer [309-312]. The anti-diabetes drug 
metformin is showing some successes in treating breast 
cancer including Herceptin-resistant breast cancers [313-
317]  A target of metformin is AMPK which is involved in 
regulation of components of the PI3K/Akt/mTORC1 and 
GSK-3 pathways. An additional target of metformin is 
Stat3 and it has been shown that metformin can inhibit the 
growth of TNBC [318]. Additional Stats may be important 
A Clinical Trial to Qualify 
the Growth Factor Signature 
(GFS) as an Intermediate 
Biomarker of Response 
for Development of PI3K-
Pathway Inhibitors in Patients 
With Breast Cancer
NCT01220570 I BC Completed
Ridaforolimus 
(mTORC1 
blocker),  
Dalotuzumab 
(IGF-1R 
inhibitor) 
Not 
provided
Phase I Parallel Protocol of 
MK-8669 (Ridaforolimus) 
+ MK-2206 and MK-8669 
(Ridaforolimus) + MK-
0752 Doublets (MK-MK) 
in Patients With Advanced 
Cancer
NCT01295632 I Advanced Cancer
Ongoing, but 
not recruiting
Ridaforolimus, 
MK-0752 
(gamma secretase 
inhibitor, a 
Notch signaling 
pathway 
inhibitor). MK-
2206
Not 
provided
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Figure 7: Induction of the Ras/Raf/MEK/ERK Pathway after Leukemia Therapy and Subsequent Effects on Cell 
Cycle Progression, Survival Pathways and Protein Translation. After chemotherapy or radiotherapy there can be activation of 
signaling pathways which can actually promote cell survival and may lead to therapy resistance. Chemotherapeutic drug treatment (shown 
in irregular black oval) frequently results in the induction of reactive oxygen species (ROS) (shown in black square). ROS can induce the 
calcium calmodulin kinase (CaM-K) cascade which can induce Ras which can subsequently activate both the Raf/MEK/ERK and PI3K/
PTEN/Akt/mTOR cascades (most components of the two cascades which promote signaling are show in green ovals, transcription factors 
activated by events are shown in yellow diamonds, transcription factors inactivated by events shown in black diamonds). Induction of the 
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways can result in the activation of many survival pathways, and regulate both cell 
cycle progression as well as protein translation. Some of the phosphorylation events mediated by Akt actually serve to inhibit the activities 
of key proteins such as the Foxo transcription factors and the murine double minute (MDM2) ubiquitin ligase (depicted in black ovals). 
MDM2 serves to regulate p53 protein stability by ubiquitination, however when it is phosphorylated by Akt it is inactivated. Moreover 
chemotherapeutic drugs and radiotherapy can induce the ataxia telangiectasia mutated (ATM) protein shown in a black oval, which can 
in turn phosphorylate and regulate p53. p53 can have complex positive and negative effects on cell growth (depicted in yellow diamond), 
it can regulate the expression of p21 cyclin dependent kinase inhibitory protein-1 (p21Cip1) which controls cell cycle progression. p53 can 
also control the transcription of genes such as Puma, Noxa and Bax which are involved in apoptosis (all of these molecules are shown in 
black ovals, as they tend to inhibit cell cycle progression or promote apoptosis). Both Akt and ERK can phosphorylate p21Cip1 which alters 
its activity and ability to inhibit cell growth (shown as black phosphorylation sites) and subsequently influence cell growth and therapy 
resistance. p27Kip1 can also be phosphorylated by both Akt and ERK, however the effects of these phosphorylation events are unclear. Akt 
phosphorylation of p27Kip1 may result in its cytoplasmic localization, while ERK phosphorylation of p27Kip1 may result in elevated levels of 
the protein. Hence phosphorylation of proteins by ERK and Akt can have dramatic effects on cell proliferation and contribute to the therapy 
resistance. Chemo- and radiotherapy also induce breaks in the DNA. In the presence of functional BRCA1 and BRCA2 (indicated in yellow 
ovals) these breaks may be repaired and normal gene transcription can occur. However when BRCA1 or BRCA2 are mutated, the repair of 
these genes may not occur and proper gene transcription might not occur. This figure serves as an introduction as to how activation of these 
pathways by chemotherapy and radiotherapy may contribute to therapeutic resistance. 
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Table 3: Targeted Agents in Combination with Cytotoxic Therapy
Official Trial Name Clinical Trial # Phase of Trial
Type of Cancer 
Patient in Trial Status of Trial Intervention Publications
Phase Ib Dose Escalation and Biomarker 
Study of MK-2206 in Combination With 
Standard Doses of Weekly Paclitaxel 
in Patients With Locally Advanced or 
Metastatic Solid Tumors With an Expansion 
in Advanced Breast Cancer
NCT01263145 I
Recurrent BC, -Stage 
IV BC,
Unspecified Adult 
Solid Tumor
Active, not 
recruiting
MK2206, paclitaxel Not 
Provided
A Phase I-II Study of Triciribine Phosphate 
Monohydrate (TCN-PM) Plus Sequential 
Weekly Paclitaxel Followed by Dose-
Dense Doxorubicin and Cyclophosphamide 
in Patients With Metastatic and Locally 
Advanced Breast Cancer
NCT01697293 I/ II
Metastatic BC, 
Carcinoma Breast 
Stage IV
Currently 
recruiting 
participants
Triciribine (an 
Akt inhibitor), 
paclitaxel, 
doxorubicin, 
cyclophosphamide
Not 
provided
A Phase Ib/II Trial of GDC-0941 (a PI3K 
Inhibitor) in Combination With Cisplatin in 
Patients With Androgen Receptor Negative 
Triple Negative Metastatic Breast Cancer
NCT01918306 I/II
ER- BC, HER- BC, 
TNBC, Recurrent 
BC, Stage IV BC 
-
Currently 
recruiting 
participants
Cisplatin, GDC-
0941, a PI3K 
inhibitor
Not 
provided 
*NeoPHOEBE: PI3k Inhibition in Her2 
OverExpressing Breast cancEr: A Phase 
II, Randomized, Parallel Cohort, Two 
Stage, Double-blind, Placebo-controlled 
Study of Neoadjuvant Trastuzumab Versus 
Trastuzumab + BKM120 in Combination 
With Weekly Paclitaxel in HER2-positive, 
PIK3CA Wild-type and PIK3CA Mutant 
Primary Breast Cancer
NCT01816594 II
HER2+, Newly 
Diagnosed, Primary 
BC
Neoadjuvant 
Therapy, 
Trastuzumab
Currently 
recruiting 
participants
BKM120, 
trastuzumab 
(trastuzumab = 
herceptin, a anti-
HER2 MoAb), 
paclitaxel 
Not 
provided
Neoadjuvant Phase II Trial of Paclitaxel in 
Combination With BKM120 in Endocrine 
Resistant Clinical Stage II or III Estrogen 
Receptor-Positive and HER2 Negative Breast 
Cancer
NCT01953445 II BC
Not yet open 
for participant 
study
Paclitaxel, BKM120
Not 
provided
A Phase Ib Trial of Gemcitabine and Cisplatin 
With RAD001 in Patients With Metastatic 
Triple Negative Breast Cancer Proceeding 
to an Open Label Randomized Phase II Trial 
Comparing Gemcitabine/Cisplatin With or 
Without RAD001.
NCT01939418 I/II Metastatic BC
Currently 
recruiting 
patients
RAD001 (Afinitor 
everolimus), 
gemcitabine (a 
nucleoside analog), 
cisplatin
Not 
provided
A Randomized, Double-Blind, Placebo-
Controlled Phase II Trial of Weekly 
Paclitaxel/Bevacizumab +/- Everolimus as 
First-Line Chemotherapy for Patients With 
HER2-Negative Metastatic Breast Cancer 
(MBC)
NCT00915603 II Metastatic BC Ongoing, but not recruiting
Everolimus,  
Bevacizumab 
(vascular 
endothelial 
growth factor A 
inhibitor), paclitaxel 
 
Not
provided 
*A Phase II Study Evaluating The Efficacy 
And Tolerability Of Everolimus (RAD001) 
In Combination With Trastuzumab And 
Vinorelbine In The Treatment Of Progressive 
HER2-Positive Breast Cancer Brain 
Metastases
NCT01305941 II HER2+ BC Recruiting
Everolimus, 
vinorelbine, 
trastuzumab (HER2 
inhibibitor, MoAb)
Not
 provided
*Phase II Study of Everolimus in 
Combination With Exemestane Versus 
Everolimus Alone Versus Capecitabine in 
the Treatment of Postmenopausal Women 
With ER+Locally Advanced, Recurrent, or 
Metastatic Breast Cancer After Recurrence 
or Progression on Prior Letrozole or 
Anastrozole.
NCT01783444 II BC Recruiting
Capecitabine (a 
pro-drug, which 
is converted to 
5-flurouracil (5-
FU) which inhibits 
thymidylate 
synthase, 
exemestane, 
Everolimus
Not 
provided
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*A Phase III Trials Program Exploring the 
Integration of Bevacizumab, Everolimus 
(RAD001), and Lapatinib Into Current 
Neoadjuvant Chemotherapy Regimes for 
Primary Breast Cancer
NCT00567554 III
BC Ongoing, but not 
recruiting
Epirubicin , 
cyclophosphamide, 
docetaxel,  
bevacizumab, 
paclitaxel,  
everolimus, 
trastuzumab, 
lapatinib
[341,342]
Phase I, Open Label, Dose Escalation 
Study of the Safety, Tolerability, and 
Pharmacokinetics of the Combination 
RAD001 Plus Docetaxel in Patients With 
Metastatic Breast Cancer
NCT00253318 I
BC Terminated
Docetaxel, RAD001, 
dexamethasone,  a 
glucocorticoid /
steroidial drugs that 
has anti-inflammatory, 
immunosuppressant 
properties
Not 
provided
Phase II, Open Label, Dose Escalation 
Study of the Safety, Tolerability, and 
Pharmacokinetics of the Combination 
RAD001 Plus Docetaxel in Patients With 
Metastatic Breast Cancer
NCT01825265 II BC
Withdrawn 
prior to 
enrollment
Docetaxel, RAD001, 
Dexamethasone
Not 
provided
*Phase 1b/2 Single-arm Trial Evaluating 
the Combination of Lapatinib, Everolimus 
and Capecitabine for the Treatment of 
Patients With HER2-positive Metastatic 
Breast Cancer With CNS Progression After 
Trastuzumab
NCT01783756 I/II
 Central Nervous 
System Metastases 
HER2+ BC, Male 
BC, Recurrent BC, 
Stage IV BC
Currently 
recruiting
Lapatinib ditosylate, 
everolimus, 
capecitabine 
Not 
provided
*A Phase Ib/II Trial of LEE011 in 
Combination With Everolimus (RAD001) 
and Exemestane in the Treatment of 
Postmenopausal Women With Estrogen 
Receptor Positive, Her2- Locally Advanced 
or Metastatic Breast Cancer
NCT01857193 I/II
BC Currently 
recruiting
LEE011, a CDK4/6 
inhibitor, exemestane, 
everolimus
Not 
provided
Phase I/II Study of Weekly Abraxane and 
RAD001 in Women With Locally Advanced 
or Metastatic Breast Cancer. A Study of the 
Cancer Institute of New Jersey Oncology 
Group (CINJOG)
NCT00934895 I/II BC
Currently 
recruiting
Everolimus, abraxane, 
abraxane is paclitaxel 
bonded to albumin as 
a delivery vehicle
Not 
provided
A Phase Ib/II Study of Cisplatin, Paclitaxel, 
and RAD001 in Patients With Metastatic 
Breast Cancer NCT01031446
I/II BC Completed
Cisplatin, everolimus, 
paclitaxel Not provided
Everolimus (RAD001) in Combination 
With Intravenous Carboplatin in Taxane- 
and Anthracycline-pretreated Patients With 
Progressive Metastatic Breast Cancer
NCT00930475 I/II BC Unknown
RAD001 in 
combination 
with carboplatin. 
Carboplatin is related 
to cisplatin, but is 
modified.
Not 
provided
Open Label Randomized Clinical Trial 
of Standard Neoadjuvant Chemotherapy 
(Paclitaxel Followed by FEC) Versus the 
Combination of Paclitaxel and RAD001 
Followed by FEC in Women With 
Triple Receptor-Negative Breast Cancer 
(CRAD001C24101)
NCT00499603 II BC Completed
Paclitaxel,  5-FU, 
epirubicin, 
cyclophosphamide, 
RAD001
Not 
provided
A Phase I Study of Cisplatin, Paclitaxel, and 
RAD001 Patients With Metastatic Breast 
Cancer NCT00680758
I BC Completed Cisplatin, everolimus, paclitaxel
Not 
provided
A Phase II Neo-Adjuvant Study of Cisplatin, 
Paclitaxel With or Without RAD001 in 
Patients With Triple-negative Locally 
Advanced Breast Cancer.
NCT00930930 II BC
Ongoing, 
but not 
recruiting
Cisplatin, everolimus, 
paclitaxel Not provided
A Phase I Pilot Study of the Oral mTOR 
Inhibitor RAD001 in Combination With 
Capecitabine for Metastatic Breast Cancer NCT00473005
I BC
Terminated 
due to 
principle 
investigator 
leaving 
sponsor
Capecitabine, 
RAD001
Not 
provided
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in the progression of breast cancer [319]. 
Drug resistance may involve multiple approaches 
such as pumping the compound out of the cell, modifying 
or detoxifying the drug, or activating survival signaling 
pathways that prevent drug-induced apoptosis [287]. ATP-
binding cassette transporters such as multidrug resistance 
protein (MRP1) and the MDR1 product, P-glycoprotein 
(Pgp), actively expel chemotherapeutic drugs from the cell 
[239,240]. Drug transporters pumps have been detected 
in a large number of untreated breast cancers, and their 
expression increases upon chemotherapy exposure [320]. 
Certain (e.g., EGFR inhibitors) targeted therapeutics 
antagonize drug transporter activity [321]. Certain CDK4 
inhibitors antagonize the response of breast cancer 
cells to antracyclines [322]. Activation of cell survival 
pathways such as PI3K/PTEN/Akt/mTORC1 pathway 
can prevent apoptosis in the presence of a drug by altering 
mitochondrial bioenergetics and inhibiting the release of 
cytochrome c and result in resistance to autophagy [323-
329]. The tumor microenvironment and metabolism may 
influence the response to targeted therapy as well as drug 
resistance of breast cancer [330]. Genes and biotargets are 
being identified which can confer resistance or sensitivity 
to other targeted therapies such as PARP inhibitors 
[331,332].
Effects of Metformin on HER2+ Breast CICs 
which are Resistant to Herceptin.
JIMT-1 is a human breast cancer cell line that 
was isolated from a pleural metastasis of a patient who 
was resistant to herceptin. CICs were isolated from this 
cell line JIMT-1(CIC). JIMT-1(CICs) were shown to be 
Phase I Study of Combined Temosirolimus, 
Erlotinib and Cisplatin in Advanced Solid 
Tumors NCT00998036
I TNBC Completed Temsirolimus, cisplatin, erlotinib
Not 
provided
A Phase Ib Study of Combination of 
Temsirolimus (Torisel®) and Pegylated 
Liposomal Doxorubicin (PLD, Doxil®/ 
Caelyx®) in Advanced or Recurrent Breast, 
Endometrial and Ovarian Cancer
NCT00982631 I
Advanced/Recurrent 
BC,  Endometrial 
Cancer, Ovarian 
Cancer
Recruitment 
is unknown 
because the 
information 
has not been 
verified 
recently
Temsirolimus/PLD Not provided
A Phase I, Open-Label, Multi-center Study 
to Assess the Safety, Tolerability and 
Pharmacokinetics of AZD6244 (ARRY-
142886) When Given in Combination With 
Standard Doses of Selected Chemotherapies 
to Patients With Advanced Solid Tumors 
NCT00600496 I
BC, Colon Cancer, 
Lung Cancer, 
Melanoma, Kidney 
Cancer
Ongoing, but 
not recruiting 
participants
AZD6244 
(MEK inhibitor), 
dacarbazine, 
Erlotinib (EGFR1 
inhibitor), 
docetaxel, 
temsirolimus
[343] 
A Phase I Study of Lenalidomide in 
Combination With Bevacizumab, Sorafenib, 
Temsirolimus, or 5-fluorouracil, Leucovorin, 
Oxaliplatin (FOLFOX) in Patients With 
Advanced Cancers
NCT01183663 I Advanced Cancers
Ongoing, but 
not recruiting
Lenalidomide 
(related to 
thalidomide), 
bevacizumab 
sorafenib (Raf 
and other kinase 
inhibitor), 
temsirolimus, 
oxaliplatin, 
leucovorin, (Folinic 
acid), 5-FU
Not 
provided
Phase I Study of Pegylated Liposomal 
Doxorubicin and Temsirolimus in Resistant 
Solid Malignancies NCT00703170
I Resistant Solid Malignancies Completed
Temsirolimus, 
pegylated liposomal 
doxorubicin
Not
provided 
A Phase I Study of the mTOR Inhibitor 
Rapamycin (Rapamune, Sirolimus) in 
Combination With Abraxane (Paclitaxel 
Protein-bound Particles) in Advanced Solid 
Cancers
NCT00337376 I Advanced Solid Cancers Terminated
Rapamune, 
Abraxane
Not
 provided
A Dose-finding Phase Ib Study Followed 
by an Open-label, Randomized Phase II 
Study of BEZ235 Plus Paclitaxel in Patients 
With HER2 Negative, Inoperable Locally 
Advanced or Metastatic Breast Cancer
NCT01495247 I/II
Inoperable Locally 
Advanced Breast 
Cancer, Metastatic 
MBC
Ongoing, but 
not recruiting BEZ235, paclitaxel
Not
 provided
Phase I Study of Docetaxel and Temsirolimus 
in Resistant Solid Malignancies NCT00703625 I
Resistant Solid 
Malignancies Completed
Temsirolimus, 
docetaxel
Not 
provided
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preferentially sensitive to the anti-diabetes drug metformin 
compared to the non-CIC JIMT(BC) population. 
Furthermore, inclusion of metformin in tumor xenograft 
studies increased the ability of Herceptin to suppress 
the growth of JIMT xenografts. These important studies 
document the potential usefulness of metformin in the 
treatment of HER2+ breast cancer patients [298]. 
Similar studies were performed with a herceptin-
sensitive (SKBR3-TzbS) and a derivative Herceptin-
resistant (SKBR3-TzbR) breast cancer cell lines. While 
herceptin inhibited the formation of mammospheres from 
herceptin-sensitive (SKBR3-TzbS), it did not suppress 
the formation of mammospheres from herceptin-resistant 
(SKBR3-TzbR) cells. Metformin would reduce the 
formation of mamospheres from both cell types but the 
SKBR3-TzbR cells were more sensitive to metformin. 
Metformin could be combined with herceptin and 
synergistically reduced mammosphere formation ability 
in SKBR-TzbR cells [333].
Induction of EMT can lead to Herceptin 
Resistance.
Induction of EMT in breast cancer is also another 
mechanism of resistance to such drugs as herceptin [334]. 
HER2 is also associated with breast cancer stem cells and 
their aggressiveness [335]. Inherent herceptin resistance 
in HER2+ breast cancers is a significant problem and 
it has been reported to be as high as 70% [334]. In the 
above study, basal HER2+ breast cancer cells resistant to 
herceptin were infected with lentiviruses containing small 
hairpin (sh) RNAs specific for EMT-specific transcription 
factors. The authors had determined appropriate genes 
to target by analysis of the public Lawrence Berkeley 
Laboratory (LBL) Breast Cancer Collection database.
These authors demonstrated that herceptin 
sensitivity was restricted to the SLUG/SNAIL2-negative 
subset of luminal/HER2+ cell lines. In contrast, breast 
cancer lines which expressed SLUG/SNAIL2 were 
inherently resistance to herceptin. Knockdown of SLUG/
SNAIL2 suppressed the CIC phenotype by upregulating 
the expression of the luminal epithelial marker CD24 in 
basal/HER2+ cells and these cells were also sensitive to 
herceptin and underwent the mesenchymal to epithelial 
transition (MET). This important study also documented 
a reduction in tumor growth and sensitivity to herceptin 
when SLUG and SNAIL2 were knocked-down in HER+ 
cells in tumor xenograft studies. This group has also 
postulated that other mechanisms may be involved in 
the induction of herceptin-refractory CICs from more 
differentiated cells via the activation of intrinsic or 
microenvironmental paths-to-stemness, also involving 
EMT [336]. 
Clinical Trials with Breast Cancer Patients 
Regarding Key Pathways Discussed.
In Tables 1-3 and Supplementary Tables 1-3, we 
present the listing of clinical trials with breast cancer 
patients derived from the ClinicalTrials.gov data base. We 
have focused our searches to the key pathways discussed 
in this review. Table 1 presents the clinical trials with 
single inhibitors (mono therapy) such as PI3K, PI3K/
mTOR, Akt, mTOR inhibitors and mTORC1 blockers 
(Everolimus, Temsirolimus, Rapamycin). Some trials have 
presented publication regarding their clinical trials, either 
in the form of abstracts or scientific manuscripts [333-
340]. In Table 2, we list the trials which have used 2 or 
more agents, usually a combination of inhibitors which 
target two different signaling pathways. Table 3 lists 
clinical trials which often combine a signal transduction 
inhibitor with chemotherapy. Some of these clinical trails 
have presented publications in the database [341-343]. 
In Supplementary Table 1, clinical trials which combine 
hormonal therapy with targeted or chemotherapy are 
presented. Some of these clinical trails have presented 
publications in the database [344-350]. Clinical trials 
using metformin as a single agent are presented in 
Supplementary Table 2. Finally clinical trails combining 
metformin and AIs and other drugs are presented in 
Supplementary Table 3 as well as a publication from one 
study [351].
SUMMARY
HER2, EGFR1, EGFRvIII and the PI3K/PTEN/Akt/
mTORC1 pathway are clearly important not only in the 
development of breast cancer, but also in the classification 
and prognosis of breast cancer patients which display 
mutations or changes in the expression of components of 
these pathways. Both HER2 and PIK3CA are aberrantly 
expressed or mutated in many breast cancers. These genes 
may be altered in breast CICs and successful targeting of 
them may prove to be effectively therapeutically. HER2 
and PI3K control the expression of many downstream 
genes involved in many different biological processes 
including protein translation and gene transcription.
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